[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 516
1. van der Meulen AA, Biber K, Lukovac S, Balasubramaniyan V, den Dunnen WF, Boddeke HW, Mooij JJ: The role of CXC chemokine ligand (CXCL)12-CXC chemokine receptor (CXCR)4 signalling in the migration of neural stem cells towards a brain tumour. Neuropathol Appl Neurobiol; 2009 Dec;35(6):579-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of CXC chemokine ligand (CXCL)12-CXC chemokine receptor (CXCR)4 signalling in the migration of neural stem cells towards a brain tumour.
  • AIMS: It has been shown that neural stem cells (NSCs) migrate towards areas of brain injury or brain tumours and that NSCs have the capacity to track infiltrating tumour cells.
  • As chemokines are involved in the migration of immune cells in the injured brain, they may also be involved in chemoattraction of NSCs towards a brain tumour.
  • METHODS: The expression profile of various chemokine receptors in NSCs, harvested from the subventricular zone of adult mice, was investigated by reverse transcriptase- polymerase chain reaction analysis.
  • RESULTS AND CONCLUSIONS: Adult mouse NSCs functionally express various chemokine receptors of which CXC chemokine receptor (CXCR)4 shows the highest mRNA levels and most pronounced functional responses in vitro.
  • In this mouse model for metastatic brain tumours, it is shown that NSCs express CXCR4 at their cell membranes while they migrate towards the tumour, which produces CXCL12.
  • [MeSH-major] Adult Stem Cells / physiology. Brain Neoplasms / physiopathology. Cell Movement / physiology. Chemokine CXCL12 / metabolism. Neurons / cytology. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Line, Tumor. Chemotaxis / physiology. Melanoma / physiopathology. Mice. Mice, Inbred C57BL. Neoplasms, Experimental / physiopathology. RNA, Messenger / metabolism. Receptors, CXCR / metabolism. Signal Transduction. Stem Cell Niche / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627512.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCR4 protein, mouse; 0 / Chemokine CXCL12; 0 / Cxcl12 protein, mouse; 0 / RNA, Messenger; 0 / Receptors, CXCR; 0 / Receptors, CXCR4; SY7Q814VUP / Calcium
  •  go-up   go-down


2. Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer; 2008 Mar;15(1):343-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-three tumor samples were tested for genetic changes using multiplex ligation-dependent probe amplification.
  • The results suggest that there may be certain progression of genetic events that involves chromosomes 1p, 3p, 6p, 11q, 12q, 17q, and 19q in the development of pheochromocytomas, and the activation of ERBB-2 located on chromosome 17q is an important and early event in the malignancy development of these tumor types.
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / genetics. Brain Neoplasms / secondary. Chromosomes, Human / genetics. Female. Genome, Human. Humans. Immunoenzyme Techniques. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):651-9 [10666394.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):453-62 [17639058.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):11-3 [11464859.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):1955-60 [11994324.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12):e57 [12060695.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1449-53 [12670888.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):707-15 [14974911.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1119-28 [15167935.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Jpn J Cancer Res. 1990 Jun-Jul;81(6-7):632-8 [1976119.001]
  • [Cites] Cancer Res. 1992 Feb 15;52(4):770-4 [1346584.001]
  • [Cites] Jpn J Cancer Res. 1993 Apr;84(4):402-8 [8514606.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):531-7 [8101147.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):151-6 [7669733.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2235-49 [9811454.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):581-91 [9844631.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1872-9 [10369850.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):260-8 [15609347.001]
  • [Cites] Diagn Mol Pathol. 2005 Mar;14(1):9-16 [15714058.001]
  • [Cites] J Pathol. 2005 Mar;205(4):514-21 [15685687.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):263-72 [15947101.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1673-84 [16236738.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):83-93 [16215979.001]
  • [Cites] Lab Invest. 2005 Dec;85(12):1481-8 [16127456.001]
  • [Cites] N Engl J Med. 2006 Jun 22;354(25):2729-31 [16790714.001]
  • [Cites] Hematol Oncol Clin North Am. 2007 Jun;21(3):509-25; ix [17548037.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):353-9 [10934139.001]
  • (PMID = 18310300.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2254511
  •  go-up   go-down


3. Fukaya R, Yoshida K, Ohira T, Kawase T: Trigeminal schwannomas: experience with 57 cases and a review of the literature. Neurosurg Rev; 2010 Apr;34(2):159-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trigeminal schwannoma is a mostly benign tumor that can be cured by complete resection.
  • Since 1990, all such patients have been treated using three main types of middle fossa skull base approaches, which minimize the exposure of the brain: the anterior transpetrosal approach, subtemporal interdural approach (Dolenc), or a combination of these approaches.
  • Before 1990, total tumor removal was achieved in only three of eight patients (38%).
  • However, total surgical removal after surgery and Gamma knife surgery was very difficult because of dense adhesions to the brain stem and cranial nerves.
  • A correct anatomical knowledge is critical for minimizing brain exposure and avoiding surgical complications.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cranial Fossa, Middle / surgery. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Radiosurgery. Retrospective Studies. Skull Base / surgery. Temporal Bone / surgery. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1986;82(3-4):118-22 [3491493.001]
  • [Cites] Acta Neurochir (Wien). 1994;130(1-4):55-65 [7725943.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(9):1027-35 [8911538.001]
  • [Cites] J Neurosurg. 1995 May;82(5):719-25 [7714595.001]
  • [Cites] Chin Med J (Engl). 2005 Mar 5;118(5):436-40 [15780219.001]
  • [Cites] Surg Neurol. 2007 Dec;68(6):594-602 [18053854.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):850-60 [3057125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Neurosurg Focus. 2008;25(6):E6; discussion E6 [19035703.001]
  • [Cites] J Neurosurg. 2007 May;106(5):839-45 [17542528.001]
  • [Cites] Neurosurgery. 2003 Apr;52(4):783-90; discussion 790 [12657173.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):18-23 [17236483.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):506-11 [2795170.001]
  • [Cites] Neurol Med Chir (Tokyo). 2005 Oct;45(10):526-9 [16247239.001]
  • [Cites] Clin Neurosurg. 1953;1:11-54 [14379464.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4 Suppl 2):ONS270-7; discussion ONS277-8 [17041497.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):752-7 [17937219.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(7):711-9 [10481782.001]
  • [Cites] Neurosurg Rev. 2007 Oct;30(4):329-37; discussion 337 [17676346.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(3-4):113-20 [7847150.001]
  • [Cites] Surg Neurol. 2004 Nov;62(5):435-44; discussion 444-6 [15518853.001]
  • [Cites] Am J Otolaryngol. 1984 Sep-Oct;5(5):301-33 [6437262.001]
  • [Cites] J Neurosurg. 1989 May;70(5):737-45 [2709114.001]
  • [Cites] Surg Neurol. 1988 Dec;30(6):452-6 [3222724.001]
  • [Cites] Pediatr Neurosci. 1987;13(4):198-201 [3331430.001]
  • [Cites] J Neurosurg Sci. 1995 Sep;39(3):165-70 [8965124.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):815-21; discussion 821-2 [14519213.001]
  • [Cites] J Neurosurg. 1999 Aug;91(2):202-11 [10433308.001]
  • [Cites] Br J Neurosurg. 1988;2(1):67-71 [3268164.001]
  • [Cites] Surg Neurol. 1975 Dec;4(6):497-503 [1188585.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):351-3 [6836494.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):233-40; discussion 240-1 [9482173.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):738-43 [18396403.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1002-7 [11958895.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):869-75; discussion 875-6 [2067611.001]
  • [Cites] J Neurosurg. 2009 Mar;110(3):553-8 [19301456.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):453-63 [11883829.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):727-32 [17937215.001]
  • [Cites] J Neurosurg. 1995 May;82(5):711-8 [7714594.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):527-34; discussion 534-6 [8875483.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):220-224 [28306474.001]
  • [Cites] Acta Neurochir (Wien). 2007 Nov;149(11):1133-7; discussion 1137 [17728994.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • (PMID = 20963463.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene; 2008 May 1;27(20):2897-909
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.
  • Tumor cells with stem cell-like properties can be cultured from human glioblastomas by using conditions that select for the expansion of neural stem cells.
  • We generated cell lines from glioblastoma specimens with the goal to obtain model systems for glioma stem cell biology.
  • Unsupervised analysis of the expression profiles of nine cell lines established under neural stem cell conditions yielded two distinct clusters.
  • Our findings show that stable, multipotent glioblastoma cell lines with a full stem-like phenotype express neurodevelopmental genes as a distinctive feature, which may offer therapeutic targeting opportunities.
  • The generation of another distinct cluster of cell lines showing similarly homogeneous profiling but restricted stem cell properties suggests that different phenotypes exist, each of which may lead to the typical appearance of glioblastoma.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Neoplastic Stem Cells / classification. Neoplastic Stem Cells / metabolism. Phenotype
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Gene Expression Profiling. Humans. Male. Mice. Mice, Nude. Middle Aged. Tumor Cells, Cultured


5. Liu YP, Lin HI, Tzeng SF: Tumor necrosis factor-alpha and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture. Brain Res; 2005 Aug 30;1054(2):152-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor necrosis factor-alpha and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture.
  • Neural progenitor cells (NPCs) in developing and adult CNS are capable of giving rise to various neuronal and glial cell populations.
  • Neurogenesis in the adult hippocampus has been found to be inhibited by a proinflammatory cytokine, interleukin-6 (IL-6), suggesting that activated microglia in the inflamed brain may control neurogenesis.
  • Treatment with pentoxifylline (PTX), an inhibitor for tumor necrosis factor-alpha (TNF-alpha) secretion from LPS-activated microglia, blocked the reduction of betaIII-tubulin+ cells in NPC culture.
  • [MeSH-major] Interleukin-18 / metabolism. Neurons / physiology. Stem Cells / physiology. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054598.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-18; 0 / Lipopolysaccharides; 0 / Tubb3 protein, rat; 0 / Tubulin; 0 / Tumor Necrosis Factor-alpha; EC 2.4.2.31 / Pertussis Toxin
  •  go-up   go-down


6. Miranda P, Ramos A, Ricoy JR: Images in neuro-oncology: brain metastases and leptomeningeal dissemination of nonseminomatous germ cell tumor. J Neurooncol; 2005 May;73(1):51-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in neuro-oncology: brain metastases and leptomeningeal dissemination of nonseminomatous germ cell tumor.
  • [MeSH-major] Brain Neoplasms / secondary. Meningeal Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / secondary. Neoplastic Stem Cells / pathology. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Embryonal Carcinoma Stem Cells. Etoposide / therapeutic use. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed


7. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, Kornblum HI: Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res; 2008 Jan;86(1):48-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.
  • Emerging evidence suggests that neural stem cells and brain tumors regulate their proliferation via similar pathways.
  • In a previous study, we demonstrated that maternal embryonic leucine zipper kinase (Melk) is highly expressed in murine neural stem cells and regulates their proliferation.
  • Here we describe how MELK expression is correlated with pathologic grade of brain tumors, and its expression levels are significantly correlated with shorter survival, particularly in younger glioblastoma patients.
  • Furthermore, we show that MELK siRNA dramatically inhibits proliferation and, to some extent, survival of stem cells isolated from glioblastoma in vitro.
  • These results demonstrate a critical role for MELK in the proliferation of brain tumors, including their stem cells, and suggest that MELK may be a compelling molecular target for treatment of high-grade brain tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Proliferation. Glioblastoma / pathology. Neoplastic Stem Cells / physiology. Protein-Serine-Threonine Kinases / physiology
  • [MeSH-minor] Adult. Aged. Animals. Cells, Cultured. Female. Flow Cytometry / methods. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Mass Spectrometry / methods. Mice. Mice, Knockout. Middle Aged. Pituitary Adenylate Cyclase-Activating Polypeptide / deficiency. RNA, Small Interfering / pharmacology. Receptors, Cell Surface / deficiency. Transfection / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722061.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA108633; United States / NCI NIH HHS / CA / CA110384; United States / NCI NIH HHS / CA / CA88173; United States / NICHD NIH HHS / HD / HD34475; United States / NINDS NIH HHS / NS / NS050151; United States / NINDS NIH HHS / NS / NS43147
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adcyap1 protein, mouse; 0 / Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 0 / patched receptors; EC 2.7.1.- / MELK protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


8. Park HY, Kim SH, Son EJ, Lee HK, Lee WS: Intracanalicular facial nerve schwannoma. Otol Neurotol; 2007 Apr;28(3):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: Pure-tone average, auditory brainstem response, caloric test, and temporal magnetic resonance imaging were done in all 11 patients.
  • MAIN OUTCOME MEASURE: Preoperative symptoms, pure-tone average, auditory brainstem response, caloric test, electroneuronography, and magnetic resonance imaging were compared between patients with facial nerve schwannomas and patients with vestibular schwannomas.
  • CONCLUSION: A facial nerve schwannoma may be misdiagnosed as a vestibular schwannoma, especially when the tumor is confined to the internal auditory canal.
  • [MeSH-minor] Adult. Aged. Audiometry, Pure-Tone. Diagnosis, Differential. Ear, Inner. Evoked Potentials, Auditory, Brain Stem / physiology. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neuroma, Acoustic / pathology. Otologic Surgical Procedures. Retrospective Studies

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414044.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Scrable H, Burns-Cusato M, Medrano S: Anxiety and the aging brain: stressed out over p53? Biochim Biophys Acta; 2009 Dec;1790(12):1587-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anxiety and the aging brain: stressed out over p53?
  • We propose a model in which cell loss in the aging brain is seen as a root cause of behavioral changes that compromise quality of life, including the onset of generalized anxiety disorder, in elderly individuals.
  • According to this model, as stem cells in neurogenic regions of the adult brain lose regenerative capacity, worn-out, dead, or damaged neurons fail to be replaced, leaving gaps in function.
  • The stress axis is subserved by all three neurogenic regions in the adult brain, making it particularly susceptible to these age-dependent changes.
  • We outline a molecular mechanism by which hyper-excitation of the stress axis in turn activates the tumor suppressor p53.
  • This reinforces the loss of stem cell proliferative capacity and interferes with the feedback mechanism by which the glucocorticoid receptor turns off neuroendocrine pathways and resets the axis.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Oct 28;310(5748):679-83 [16254185.001]
  • [Cites] Neurobiol Aging. 2006 Apr;27(4):645-54 [15953661.001]
  • [Cites] Brain Res. 2006 Aug 2;1102(1):44-51 [16806117.001]
  • [Cites] Nat Neurosci. 2007 Mar;10(3):355-62 [17277773.001]
  • [Cites] Nat Neurosci. 2007 Jun;10(6):727-34 [17486101.001]
  • [Cites] J Comp Neurol. 2007 Nov 10;505(2):209-20 [17853440.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15570-5 [18832146.001]
  • [Cites] Neurobiol Aging. 2009 Mar;30(3):483-97 [17850928.001]
  • [Cites] Neuroscience. 2009 Feb 18;158(4):1378-89 [19038313.001]
  • [Cites] Neuroreport. 2009 Apr 22;20(6):553-7 [19322118.001]
  • [Cites] Nature. 2002 Feb 28;415(6875):1030-4 [11875571.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 2002 May;132(1):1-15 [11997205.001]
  • [Cites] FASEB J. 2002 Jun;16(8):761-70 [12039857.001]
  • [Cites] Cell. 2002 Aug 23;110(4):429-41 [12202033.001]
  • [Cites] Hippocampus. 2002;12(5):578-84 [12440573.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9747-53 [12519780.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 2003 Spring;15(2):180-6 [12724459.001]
  • [Cites] Eur J Neurosci. 2003 May;17(10):2042-6 [12786970.001]
  • [Cites] Trends Neurosci. 2003 Jun;26(6):292-6 [12798597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9023-7 [12853570.001]
  • [Cites] Int J Geriatr Psychiatry. 2003 Oct;18(10):951-9 [14533128.001]
  • [Cites] Mol Psychiatry. 2009 Oct;14(10):959-67 [19255582.001]
  • [Cites] J Neurosci. 2001 Sep 15;21(18):7153-60 [11549726.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1823-8 [10677540.001]
  • [Cites] Nature. 2001 Mar 15;410(6826):372-6 [11268214.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2764-72 [11358490.001]
  • [Cites] Genes Dev. 2004 Feb 1;18(3):306-19 [14871929.001]
  • [Cites] J Neurosci. 2004 Feb 18;24(7):1726-33 [14973255.001]
  • [Cites] Clin Geriatr Med. 2003 Nov;19(4):721-41 [15024809.001]
  • [Cites] J Neurosci. 2004 Mar 24;24(12):2886-97 [15044527.001]
  • [Cites] J Neurosci. 2004 Sep 22;24(38):8354-65 [15385618.001]
  • [Cites] Biochim Biophys Acta. 2004 Oct 21;1680(2):114-28 [15488991.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Arch Gen Psychiatry. 1983 Nov;40(11):1167-73 [6139099.001]
  • [Cites] Gerontologist. 1984 Feb;24(1):23-30 [6698411.001]
  • [Cites] J Psychol. 1984 Mar;116(2d Half):159-67 [6609232.001]
  • [Cites] J Am Geriatr Soc. 1985 Apr;33(4):246-52 [3989185.001]
  • [Cites] Am J Psychiatry. 1986 Nov;143(11):1471-2 [3777244.001]
  • [Cites] Arch Gen Psychiatry. 1987 May;44(5):473-80 [3555383.001]
  • [Cites] Br J Psychiatry. 1989 Sep;155:317-29 [2611541.001]
  • [Cites] J Neurosci. 1990 Oct;10(10):3247-54 [2170594.001]
  • [Cites] J Comp Neurol. 1990 Nov 15;301(3):365-81 [2262596.001]
  • [Cites] J Am Geriatr Soc. 1992 Jul;40(7):727-33 [1607591.001]
  • [Cites] Neurosci Lett. 1993 Jan 12;149(2):111-4 [8474679.001]
  • [Cites] Neuron. 1993 Jul;11(1):173-89 [8338665.001]
  • [Cites] Neuroscience. 1993 Sep;56(2):337-44 [8247264.001]
  • [Cites] Stroke. 1996 Feb;27(2):270-5 [8571422.001]
  • [Cites] Psychosomatics. 1996 Jan-Feb;37(1):31-7 [8600492.001]
  • [Cites] J Neurosci. 1996 Mar 15;16(6):2027-33 [8604047.001]
  • [Cites] Neuroreport. 1995 Dec 15;6(18):2479-82 [8741746.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14895-900 [8962152.001]
  • [Cites] Arch Fam Med. 1997 Jan-Feb;6(1):43-9 [9003169.001]
  • [Cites] Psychol Med. 1997 Jan;27(1):91-8 [9122313.001]
  • [Cites] Circulation. 1997 Feb 18;95(4):818-24 [9054737.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] J Neurosci. 1997 Oct 15;17(20):7850-9 [9315905.001]
  • [Cites] J Behav Ther Exp Psychiatry. 1997 Dec;28(4):269-79 [9489688.001]
  • [Cites] J Neurosci. 1998 May 1;18(9):3206-12 [9547229.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Int J Geriatr Psychiatry. 1998 Oct;13(10):717-26 [9818308.001]
  • [Cites] Nat Neurosci. 1998 May;1(1):69-73 [10195112.001]
  • [Cites] Nat Neurosci. 1999 Mar;2(3):260-5 [10195219.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5263-7 [10220454.001]
  • [Cites] Aten Primaria. 1999 Mar 31;23(5):275-9 [10341458.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Psychol Med. 1999 May;29(3):583-93 [10405079.001]
  • [Cites] J Comp Neurol. 1999 Oct 11;413(1):146-54 [10464376.001]
  • [Cites] Nat Neurosci. 1999 Oct;2(10):894-7 [10491610.001]
  • [Cites] Exp Neurol. 2005 Apr;192(2):251-64 [15755543.001]
  • (PMID = 19800395.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG026094-04; United States / NIA NIH HHS / AG / R01 AG026094; United States / NIA NIH HHS / AG / R01 AG032679; United States / NIA NIH HHS / AG / R01 AG026094-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Glucocorticoid; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 72
  • [Other-IDs] NLM/ NIHMS154831; NLM/ PMC2784097
  •  go-up   go-down


10. Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J, Essensten M, Forman S, Somlo G: Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. Biol Blood Marrow Transplant; 2006 Mar;12(3):306-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A method to deliver a more targeted dose of TBI preferentially to sites of greatest tumor burden is needed to reduce the dose to normal organs, reduce toxicities, and permit dose escalation.
  • Whole-body computed tomography datasets from 3 patients, age 5, 20, and 53 years, were used for treatment planning studies to evaluate 2 targeted TBI strategies: total marrow irradiation (TMI), in which the target region was defined as the skeletal bone, and total marrow and lymphoid irradiation (TMLI), in which the target regions were defined as bone, major lymph node chains, liver, spleen, and sanctuary sites, such as brain.
  • Results were similar for the adult and pediatric patients, indicating that this form of targeted TBI will be applicable to most patients regardless of frame size.
  • Ongoing clinical trials will define the maximum TMI and TMLI doses achievable and define the potential advantages and limitations of this new approach for patients undergoing hematopoietic stem cell transplantation.
  • [MeSH-minor] Adult. Child, Preschool. Female. Humans. Middle Aged. Radiotherapy Dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16503500.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Maruya J, Narita E, Nishimaki K, Heianna J, Miyauchi T, Minakawa T: Primary cystic germinoma originating from the midbrain. J Clin Neurosci; 2009 Jun;16(6):832-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following chemotherapy and radiotherapy, the symptoms improved and the tumor disappeared.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Central Nervous System Cysts / pathology. Germinoma / pathology. Mesencephalon / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Biopsy. Carboplatin / administration & dosage. Diplopia / etiology. Etoposide / administration & dosage. Humans. Male. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299138.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Acioly MA, Carvalho CH, Koerbel A, Löwenheim H, Tatagiba M, Gharabaghi A: Intraoperative brainstem auditory evoked potential observations after trigeminocardiac reflex during cerebellopontine angle surgery. J Neurosurg Anesthesiol; 2010 Oct;22(4):347-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative brainstem auditory evoked potential observations after trigeminocardiac reflex during cerebellopontine angle surgery.
  • BACKGROUND: The occurrence of trigeminocardiac reflex (TCR) is known to be a negative prognostic factor for hearing preservation in cerebellopontine angle tumor surgery.
  • Our study was conducted to investigate brainstem auditory evoked potential (BAEP) changes after this reflex in cerebellopontine angle tumor surgery and to evaluate their impact on postoperative hearing function.
  • [MeSH-major] Cerebellopontine Angle / surgery. Evoked Potentials, Auditory, Brain Stem / physiology. Heart / physiology. Reflex / physiology. Trigeminal Nerve / physiology
  • [MeSH-minor] Adolescent. Adult. Anesthesia. Audiometry, Pure-Tone. Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Epidermal Cyst / surgery. Female. Hearing. Humans. Male. Meningioma / surgery. Monitoring, Intraoperative. Neurilemmoma / surgery. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20706143.001).
  • [ISSN] 1537-1921
  • [Journal-full-title] Journal of neurosurgical anesthesiology
  • [ISO-abbreviation] J Neurosurg Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Mehta VS, Chandra PS, Singh PK, Garg A, Rath GK: Surgical considerations for 'intrinsic' brainstem gliomas: proposal of a modification in classification. Neurol India; 2009 May-Jun;57(3):274-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical considerations for 'intrinsic' brainstem gliomas: proposal of a modification in classification.
  • BACKGROUND: Brainstem gliomas are highly heterogeneous tumors both in their clinical manifestation and in their pathology.
  • Despite significant advances in the surgery for brainstem gliomas many aspects of this pathology are still unclear.
  • OBJECTIVE: To evaluate the clinical, radiological and surgical outcome of 40 focal 'intrinsic' brainstem gliomas and propose a surgical strategy-oriented classification.
  • Our criteria included patients with (1) well-defined gadolinium enhancing tumor;.
  • RESULTS: The 'intrinsic' brainstem tumors were classified into three types: Expanding, diffuse infiltrative and pure ventral varieties.
  • Only patients with expanding variety of brainstem gliomas were subjected to surgery, mean age 19.2 years (range 4-55 years) and male to female ration mean: 3:2).
  • The tumor location included pons (n=19), midbrain (n=13) and medulla (n=8).
  • CONCLUSION: The surgical management of intrinsic brainstem tumors presents a surgical challenge; radical excision yielded a good outcome in the majority of cases.
  • The authors propose a classification system for 'intrinsic' brainstem tumors for defining surgical strategy.
  • [MeSH-major] Brain Stem Neoplasms / classification. Brain Stem Neoplasms / surgery. Glioma / classification. Glioma / surgery. Neurosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurol India. 2009 May-Jun;57(3):231-2 [19587459.001]
  • (PMID = 19587467.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Fujishima N, Fujishima M, Inomata M, Yamanaka Y, Saitoh K, Kameoka Y, Yoshioka T, Saitoh H, Takahashi N, Hirokawa M, Sawada K: [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy]. Rinsho Ketsueki; 2007 Apr;48(4):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 43-year-old female was admitted with therapy-resistant pancreatitis and an abdominal tumor around the pancreatic head.
  • Although CODOX-M and IVAC therapy combined with rituximab achieved complete remission, she died of rapid progressive disease during whole brain irradiation before autologous peripheral blood stem cell transplantation.
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Methotrexate / administration & dosage. Recurrence. Remission Induction. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515125.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


15. Kumabe T, Fujimura M, Jokura H, Tominaga T: Surgical treatment for choroid plexus tumors in the fourth ventricle: brain stem infiltration hinders total extirpation. Neurosurg Rev; 2008 Apr;31(2):165-72; discussion 172
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for choroid plexus tumors in the fourth ventricle: brain stem infiltration hinders total extirpation.
  • Preoperative T2-weighted magnetic resonance imaging showed a diffuse high-intensity lesion in the brain stem in four patients.
  • No patient suffered tumor progression within the follow-up of 24-129 months (mean 64 months).
  • Adjuvant therapy for choroid plexus tumors with brain stem infiltration must be established.
  • [MeSH-major] Brain Stem / pathology. Carcinoma / surgery. Cerebral Ventricle Neoplasms / surgery. Choroid Plexus Neoplasms / surgery. Fourth Ventricle / surgery. Neurosurgical Procedures. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Cerebral Hemorrhage / therapy. Child, Preschool. Female. Humans. Intraoperative Complications / therapy. Laminectomy. Magnetic Resonance Imaging. Male. Pregnancy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]
  • [Cites] No Shinkei Geka. 2006 Jan;34(1):73-81 [16440700.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):257-64 [11213963.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):563-6 [1383866.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] No Shinkei Geka. 1997 Sep;25(9):853-7 [9300457.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-202-6; discussion ONS-206-7 [16582641.001]
  • [Cites] J Neurosurg. 1975 Aug;43(2):225-32 [1185253.001]
  • [Cites] No Shinkei Geka. 1991 Jan;19(1):21-6 [2000153.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] Acta Neurochir (Wien). 2005 Feb;147(2):137-42; discussion 142 [15605202.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):303-9 [11220372.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3 Suppl):S7-27 [10983303.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • (PMID = 17912563.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Chojnacki A, Weiss S: Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells. Nat Protoc; 2008;3(6):935-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of neurons, astrocytes and oligodendrocytes from mammalian CNS stem cells.
  • The discovery of neural stem cells in the adult mouse brain was made possible by the creation of a novel culture system subsequently termed the neurosphere assay.
  • Therein, the dissociated adult mouse periventricular area was plated in the presence of epidermal growth factor, but in the absence of adhesive substrates, which resulted in the generation of spheres of proliferating cells that detached from the plate bottom and remained suspended in the media.
  • Since its inception, the neurosphere culture system has been widely used in the neural precursor cell field and has been extensively adapted for the isolation and expansion of corneal, cardiac, skin, prostate, mammary and brain tumor stem cells.
  • [MeSH-major] Astrocytes / cytology. Cell Separation / methods. Embryonic Stem Cells / cytology. Neurons / cytology. Oligodendroglia / cytology
  • [MeSH-minor] Animals. Brain / cytology. Brain / embryology. Cell Culture Techniques / methods. Cell Differentiation. Female. Humans. Mice. Multipotent Stem Cells / cytology. Pregnancy

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536641.001).
  • [ISSN] 1750-2799
  • [Journal-full-title] Nature protocols
  • [ISO-abbreviation] Nat Protoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Schipani S, Jain R, Shah K, Rock JP, Movsas B, Rosenblum M, Ryu S: Clinical, dosimetric, and radiographic correlation of radiation injury involving the brainstem and the medial temporal lobes following stereotactic radiotherapy for neoplasms of central skull base. J Neurooncol; 2010 Jun;98(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, dosimetric, and radiographic correlation of radiation injury involving the brainstem and the medial temporal lobes following stereotactic radiotherapy for neoplasms of central skull base.
  • Mean time interval between SRT and detection of RI was 9 +/- 3, 18.5 +/- 5, and 13.5 months for brainstem, temporal lobe, and cerebellum/labyrinth lesions, respectively.
  • RI can occur around the skull base because of irregular shape of target tumor, its close proximity to normal brain parenchyma, and inhomogeneity of dose distribution.
  • Brainstem lesions occurred earlier than temporal lobe RI.
  • The majority of the RI lesions, not mixed with the tumor in this study, showed radiographic and clinical improvement with steroid and symptomatic treatments.
  • [MeSH-major] Brain Stem / pathology. Radiation Injuries / pathology. Radiosurgery / adverse effects. Skull Base Neoplasms / surgery. Temporal Lobe / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiometry / methods. Radiotherapy Dosage. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1327-32 [11498461.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):2013-8 [12673732.001]
  • [Cites] Nucl Med Commun. 1999 May;20(5):411-7 [10404525.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Sep;26(8):1967-72 [16155144.001]
  • [Cites] Circulation. 2003 Jul 29;108(4):426-31 [12860913.001]
  • [Cites] Cancer. 1997 Nov 15;80(10):2005-12 [9366305.001]
  • [Cites] Stereotact Funct Neurosurg. 2008;86(6):359-66 [18854663.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Apr;22(4):613-24 [11290467.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:229-36 [9782255.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1055-63 [8985027.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1143-8 [10725624.001]
  • [Cites] Radiother Oncol. 1997 Jun;43(3):275-80 [9215787.001]
  • [Cites] J Neurosurg. 2001 Jun;94(6):899-904 [11409517.001]
  • [Cites] Neurosurgery. 2007 Oct;61(4):778-86; discussion 786-7 [17986939.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Jun;130(6):690-7 [15195054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):273-8 [9457809.001]
  • [Cites] J Nucl Med. 2000 Nov;41(11):1861-7 [11079496.001]
  • [Cites] Am J Otolaryngol. 2007 Sep-Oct;28(5):338-41 [17826537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):485-90 [9231670.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13 [14768726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):796-808 [15183483.001]
  • [Cites] Surg Neurol. 2009 Aug;72(2):162-7; discussion 167-8 [18786715.001]
  • [Cites] Surg Neurol. 1978 Nov;10(5):281-90 [364708.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):699-705 [10524425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):323-6 [17236958.001]
  • [Cites] J Neurooncol. 2007 Apr;82(2):119-24 [17004100.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):191-7 [11410888.001]
  • [Cites] Radiology. 2000 Nov;217(2):377-84 [11058631.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):E579; discussion E579 [17327770.001]
  • [Cites] Ann Neurol. 2003 Jun;53(6):743-51 [12783420.001]
  • [Cites] Radiat Res. 2004 Feb;161(2):137-42 [14731077.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] J Neurol Sci. 2008 Dec 15;275(1-2):164-6 [18804790.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Aug;43(8):391-5 [12968806.001]
  • [Cites] J Neuroophthalmol. 2004 Sep;24(3):195-9 [15348983.001]
  • (PMID = 20376551.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Xiong J, Chu SG, Wang Y, Zhu JJ, Li C, Mao Y: Metastasis of renal cell carcinoma to a haemangioblastoma of the medulla oblongata in von Hippel-Lindau syndrome. J Clin Neurosci; 2010 Sep;17(9):1213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a small area, the tumor showed abundant thin-walled vessels and clear cells.
  • Immunohistochemically, staining for cytokeratin, epithelial membrane antigen and CD10 was typically positive in the tumor portion that contained RCC but not in the HAB.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Carcinoma, Renal Cell / diagnosis. Hemangioblastoma / diagnosis. Hemangioblastoma / secondary. Kidney Neoplasms / diagnosis. von Hippel-Lindau Disease / diagnosis
  • [MeSH-minor] Adult. Humans. Male. Medulla Oblongata / pathology


19. Suzuki T, Izumoto S, Wada K, Fujimoto Y, Maruno M, Yamasaki M, Kanemura Y, Shimazaki T, Okano H, Yoshimine T: Inhibition of glioma cell proliferation by neural stem cell factor. J Neurooncol; 2005 Sep;74(3):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of glioma cell proliferation by neural stem cell factor.
  • Neural stem cells (NSC) have unique differentiation-, proliferation-, and motility properties.
  • To investigate whether they secrete factors that interfere with the proliferation of glioma cells, we grew glioma cells in conditioned medium (CM) obtained from cultures of neurospheres including neural stem / progenitor cells (NSPC) isolated from embryonic (E14)- or adult mouse brain or fetal human brain.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Proliferation / drug effects. Culture Media, Conditioned / pharmacology. Glioma / pathology. Stem Cells / secretion
  • [MeSH-minor] Animals. Cell Line, Tumor. Corpus Striatum / cytology. Embryo, Mammalian. Humans. Immunohistochemistry. Mice. Neurons / cytology. Rats. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1996 Aug 25;178(1):77-89 [8812110.001]
  • [Cites] Acta Pathol Microbiol Scand. 1968;74(4):465-86 [4313504.001]
  • [Cites] Science. 1968 Jul 26;161(3839):370-1 [4873531.001]
  • [Cites] Development. 1990 Dec;110(4):1001-20 [2100251.001]
  • [Cites] Dev Biol. 1999 Nov 1;215(1):118-29 [10525354.001]
  • [Cites] Adv Pharmacol. 1997;37:35-67 [8891099.001]
  • [Cites] Acta Neuropathol. 1999 Apr;97(4):393-8 [10208279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Matrix Biol. 2000 Sep;19(5):377-87 [10980414.001]
  • [Cites] J Neurosci. 1998 Oct 1;18(19):7869-80 [9742155.001]
  • [Cites] J Neurosci Res. 1993 Aug 1;35(5):567-76 [8377226.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Acta Neuropathol. 1980;51(1):23-31 [7435138.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] Cancer Res. 1973 May;33(5):976-86 [4703128.001]
  • [Cites] J Cell Physiol. 1979 Apr;99(1):43-54 [222778.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1440-4 [8640837.001]
  • [Cites] Eur J Neurosci. 1999 Feb;11(2):503-16 [10051751.001]
  • [Cites] J Neurosci. 1995 Aug;15(8):5765-78 [7643217.001]
  • [Cites] Development. 2000 Nov;127(22):4993-5005 [11044412.001]
  • [Cites] Nat Med. 2000 Apr;6(4):447-50 [10742153.001]
  • [Cites] J Neurosci. 1999 Oct 15;19(20):8954-65 [10516314.001]
  • [Cites] Can J Neurol Sci. 1983 May;10(2):105-9 [6861007.001]
  • [Cites] Acta Neuropathol. 1992;84(2):190-7 [1523973.001]
  • [Cites] Differentiation. 2001 Sep;68(2-3):141-52 [11686236.001]
  • (PMID = 16187020.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned
  •  go-up   go-down


20. Glas M, Rath BH, Simon M, Reinartz R, Schramme A, Trageser D, Eisenreich R, Leinhaas A, Keller M, Schildhaus HU, Garbe S, Steinfarz B, Pietsch T, Steindler DA, Schramm J, Herrlinger U, Brüstle O, Scheffler B: Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol; 2010 Aug;68(2):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual tumor cells are unique cellular targets in glioblastoma.
  • Residual tumor cells remain beyond the margins of every glioblastoma (GBM) resection.
  • In this study, residual tumor cells were derived via experimental biopsy of the resection margin after standard neurosurgery for direct comparison with samples from the routinely resected tumor tissue.
  • In vitro analysis of proliferation, invasion, stem cell qualities, GBM-typical antigens, genotypes, and in vitro drug and irradiation challenge studies revealed these cells as unique entities.
  • Our findings suggest a need for characterization of residual tumor cells to optimize diagnosis and treatment of GBM.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20695020.001).
  • [ISSN] 1531-8249
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS055165; United States / NINDS NIH HHS / NS / NS055165
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ NIHMS686096; NLM/ PMC4445859
  •  go-up   go-down


21. Tedeschi A, Di Giovanni S: The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep; 2009 Jun;10(6):576-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indeed, p53 has a crucial role in eliciting neuronal cell death during development and in adult organisms after exposure to a range of stressors and/or DNA damage.
  • [MeSH-major] Apoptosis. Neurons / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Nervous System / embryology. Nervous System / metabolism. Protein Processing, Post-Translational. Signal Transduction. Stem Cells / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2001 May 18;497(1):20-5 [11376656.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):44-51 [11550301.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6503-15 [11641774.001]
  • [Cites] Neoplasia. 2002 Jan-Feb;4(1):82-7 [11922394.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] J Neurosci. 2002 Nov 15;22(22):9800-9 [12427836.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):164-71 [12648672.001]
  • [Cites] Cell Death Differ. 2003 Apr;10(4):400-3 [12719715.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5208-19 [12910258.001]
  • [Cites] Neuron. 2003 Oct 9;40(2):199-208 [14556704.001]
  • [Cites] J Neurotrauma. 2003 Dec;20(12):1271-92 [14748977.001]
  • [Cites] Prog Neurobiol. 2004 Jan;72(1):1-25 [15019174.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):822-42 [15095006.001]
  • [Cites] Neuroscientist. 2004 Oct;10(5):443-55 [15359011.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2851-5 [3915536.001]
  • [Cites] Biochim Biophys Acta. 1988 Sep 7;950(3):395-402 [3048409.001]
  • [Cites] Development. 1991 Nov;113(3):857-65 [1821855.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):175-80 [7663512.001]
  • [Cites] Curr Biol. 1995 Aug 1;5(8):931-6 [7583151.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1335-41 [8657106.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5178-85 [8756675.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1381-90 [9135153.001]
  • [Cites] EMBO J. 1997 Mar 17;16(6):1391-400 [9135154.001]
  • [Cites] Oncogene. 1997 Jul 17;15(3):245-56 [9233759.001]
  • [Cites] J Biol Chem. 1997 Sep 19;272(38):24002-7 [9295352.001]
  • [Cites] J Comp Neurol. 1998 Jul 27;397(2):181-98 [9658283.001]
  • [Cites] J Cell Biol. 1998 Dec 14;143(6):1691-703 [9852160.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):664-73 [9880587.001]
  • [Cites] Cell Mol Life Sci. 1999 Jan;55(1):38-47 [10065150.001]
  • [Cites] Prog Neurobiol. 1999 Feb;57(4):421-50 [10080384.001]
  • [Cites] J Neurosci. 2004 Nov 3;24(44):10003-12 [15525786.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55667-74 [15496412.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11851-8 [15598651.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):761-77 [15865932.001]
  • [Cites] Prog Neurobiol. 2005 Mar;75(4):275-93 [15882777.001]
  • [Cites] FEBS J. 2005 Jun;272(11):2628-38 [15943798.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):22-47 [15960985.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1057-65 [15818407.001]
  • [Cites] Neuron. 2005 Dec 8;48(5):743-56 [16337913.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Cell Death Differ. 2006 Jun;13(6):941-50 [16601750.001]
  • [Cites] Prog Neurobiol. 2006 Apr;78(6):347-63 [16716487.001]
  • [Cites] J Neurochem. 2006 Jun;97(6):1571-84 [16805769.001]
  • [Cites] Nat Rev Neurosci. 2006 Aug;7(8):603-16 [16858389.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1499-511 [16939971.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1575-92 [16939976.001]
  • [Cites] EMBO J. 2006 Sep 6;25(17):4084-96 [16946709.001]
  • [Cites] Cell Death Differ. 2006 Dec;13(12):2118-28 [16729028.001]
  • [Cites] Nucleic Acids Res. 2006;34(22):6640-52 [17145718.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):312-7 [17264677.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1451-60 [17308083.001]
  • [Cites] J Cell Biochem. 2007 Mar 1;100(4):883-96 [17031865.001]
  • [Cites] Cell Death Differ. 2007 May;14(5):973-81 [17218959.001]
  • [Cites] Nat Rev Neurosci. 2007 May;8(5):368-78 [17453017.001]
  • [Cites] BMC Genomics. 2007;8:139 [17540029.001]
  • [Cites] Cell Cycle. 2007 Jun 15;6(12):1412-4 [17581277.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 May;9(5):402-12 [18431400.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Sep;9(9):702-12 [18719709.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Oct;9(10):815-20 [18784729.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):172-82 [19151705.001]
  • [Cites] Neuroscience. 2009 Feb 18;158(4):1378-89 [19038313.001]
  • [Cites] Cell Death Differ. 2009 Apr;16(4):543-54 [19057620.001]
  • [Cites] J Neurochem. 2006 Mar;96(6):1501-8 [16476081.001]
  • [Cites] Nature. 2000 Apr 20;404(6780):897-900 [10786799.001]
  • [Cites] Science. 2000 Jul 14;289(5477):304-6 [10894779.001]
  • [Cites] Mutat Res. 2000 Sep 18;452(2):149-62 [11024475.001]
  • [Cites] Cell. 2000 Sep 15;102(6):849-62 [11030628.001]
  • [Cites] J Biol Chem. 2000 Dec 1;275(48):37829-37 [10978315.001]
  • [Cites] Adv Neurol. 2001;87:25-40 [11347228.001]
  • (PMID = 19424293.001).
  • [ISSN] 1469-3178
  • [Journal-full-title] EMBO reports
  • [ISO-abbreviation] EMBO Rep.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R21 NS052640
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 75
  • [Other-IDs] NLM/ PMC2711843
  •  go-up   go-down


22. Demir O, Singh S, Klimaschewski L, Kurnaz IA: From birth till death: neurogenesis, cell cycle, and neurodegeneration. Anat Rec (Hoboken); 2009 Dec;292(12):1953-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, proliferative cells still exist within the nervous system, and adult neural stem cells (NSCs) have been identified in the Central Nervous System (CNS) in the past decade, raising a great stir in the neuroscience community.
  • Tumor formation may be regarded as a de-differentiation of tissues, where cell cycle mechanisms are reactivated in differentiated cell types.
  • It is thus important to understand the molecular mechanisms underlying various brain tumors in this perspective.
  • The recent Cancer Stem Cell (CSC) hypothesis also suggests the presence of Brain Tumor Initiating Cells (BTICs) within a tumor population, although the exact origin of these rare and mostly elusive BTICs are yet to be identified.
  • This review attempts to investigate the correlation of neural stem cells/precursors, mature neurons, BTICs and brain tumors with respect to cell cycle regulation and the impact of cell cycle in neurodegeneration.
  • [MeSH-major] Cell Cycle / physiology. Cell Transformation, Neoplastic / genetics. Central Nervous System / embryology. Central Nervous System / physiology. Nerve Degeneration / physiopathology. Neurogenesis / physiology. Stem Cells / physiology
  • [MeSH-minor] Animals. Cell Differentiation / physiology. Cell Lineage / physiology. Humans. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19943348.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


23. Kanno H, Yamamoto I, Nishikawa R, Matsutani M, Wakabayashi T, Yoshida J, Shitara N, Yamasaki I, Shuin T, Clinical VHL Research Group in Japan: Spinal cord hemangioblastomas in von Hippel-Lindau disease. Spinal Cord; 2009 Jun;47(6):447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among these 48 patients, 46 of them (95.8%) also had a central nervous system (CNS) hemangioblastoma at another site: 42 (87.5%) with cerebellar hemangioblastoma and 11 (22.9%) with brain stem hemangioblastoma.
  • The tumor was accompanied with a syrinx in 64 and without it in 10 patients.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Neurologic Examination. Retrospective Studies. Severity of Illness Index. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030009.001).
  • [ISSN] 1476-5624
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Ibayashi Y; Yamaki T; Numagami Y; Jokura E; Kayama Y; Yamada Y; Shiokawa Y; Yamashita J; Hasegawa M; Hatano H; Shinoda J; Sakai N; Taki W; Matsushima S; Murao K; Matsubara T; Takahashi JA; Matsumoto K; Nakajima H; Hashimoto M; Matsumoto S; Ichigizaki K; Murase I; Kashiwabara K; Yamakawa Y; Yamazaki H; Kubo S; Tokuda K; Abiko S; Miyazaki H; Anda T; Shibata S; Miyamoto T; Okawa N; Morimoto S; Inoue M; Miyagami M
  •  go-up   go-down


24. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong SC, Park WY, Lee DS, Kim H, Nam DH: Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest; 2008 Aug;88(8):808-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A number of recent reports have demonstrated that only CD133-positive cancer cells of glioblastoma multiforme (GBM) have tumor-initiating potential.
  • These findings raise an attractive hypothesis that GBMs can be cured by eradicating CD133-positive cancer stem cells (CSCs), which are a small portion of GBM cells.
  • Both CD133-positive and CD133-negative cells purified from four out of six GBM patients produced typical GBM tumor masses in NOD-SCID brains, whereas brain mass from CD133-negative cells showed more proliferative and angiogenic features compared to that from CD133-positive cells.
  • Our results suggest, in contrast to previous reports that only CD133-positive cells of GBMs can initiate tumor formation in vivo CD133-negative cells also possess tumor-initiating potential, which is indicative of complexity in the identification of cancer cells for therapeutic targeting.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / immunology. Glioblastoma / immunology. Glycoproteins / metabolism. Neoplastic Stem Cells / immunology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Brain / pathology. Cells, Cultured. Drug Resistance, Neoplasm / immunology. Female. Gene Expression Profiling. Humans. Male. Mice. Mice, SCID. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18560366.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


25. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI: Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells; 2009 Apr;27(4):980-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renewable neurosphere formation in culture is a defining characteristic of certain brain tumor initiating cells.
  • Tumor samples were cultured in neurosphere conditions from 32 patients with glioma, including a subpopulation of 15 patients with primary glioblastoma.
  • A subsample of renewable neurosphere cultures was xenografted into mouse brain to determine if they were tumorigenic.
  • Renewable neurosphere formation in cultured human glioma significantly predicted an increased hazard of patient death and more rapid tumor progression.
  • In addition, multivariate analysis of neurosphere formation, tumor grade and patient age, demonstrated that neurosphere formation was a robust, independent predictor of glioma tumor progression.
  • Furthermore, this study suggests that the ability to propagate brain tumor stem cells in vitro is associated with clinical outcome.


26. Lepore AC, Neuhuber B, Connors TM, Han SS, Liu Y, Daniels MP, Rao MS, Fischer I: Long-term fate of neural precursor cells following transplantation into developing and adult CNS. Neuroscience; 2006 Sep 29;142(1):287-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term fate of neural precursor cells following transplantation into developing and adult CNS.
  • Few studies have examined the long-term properties of transplanted neural precursor cells in the CNS, particularly in non-neurogenic regions of the adult.
  • The aim of the present study was to extensively characterize the fate of defined populations of neural precursor cells following transplantation into the developing and adult CNS (brain and spinal cord) for up to 15 months, including integration of graft-derived neurons with the host.
  • We found that in both developing and adult CNS grafted cells showed long-term survival, morphological maturation, extensive distribution and differentiation into all mature CNS cell types (neurons, astrocytes and oligodendrocytes).
  • Graft-derived neurons also formed synapses, as identified by electron microscopy, suggesting that transplanted neural precursor cells integrated with adult CNS.
  • We did not detect tumor formation, cells did not localize to unwanted locations and no pronounced immune response was present at the graft sites.
  • [MeSH-major] Cell Differentiation / physiology. Central Nervous System / physiology. Neurons / physiology. Stem Cell Transplantation / methods. Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Neuroscience. 2006 May 12;139(2):513-30 [16458439.001]
  • (PMID = 17120358.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 37515; United States / NINDS NIH HHS / NS / NS24707
  • [Publication-type] Comparative Study; Corrected and Republished Article; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Immunosuppressive Agents; 0 / Nerve Tissue Proteins; 0 / Neural Cell Adhesion Molecules; 0 / ganglioside A2B5
  •  go-up   go-down


27. Venkateswaran RV, Dronavalli V, Lambert PA, Steeds RP, Wilson IC, Thompson RD, Mascaro JG, Bonser RS: The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation; 2009 Aug 27;88(4):582-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Brain stem death can elicit a potentially manipulable cardiotoxic proinflammatory cytokine response.
  • METHODS: In a prospective randomized double-blinded factorially designed study of T3 and MP therapy, we measured serum levels of interleukin-1 and -6 (IL-1 and IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein, and procalcitonin (PCT) levels in 79 potential heart or lung donors.
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / administration & dosage. Biomarkers / blood. Brain Death. Brain Stem / physiopathology. C-Reactive Protein / metabolism. Calcitonin / blood. Double-Blind Method. Female. Humans. Interleukin-1 / blood. Interleukin-6 / blood. Male. Methylprednisolone / administration & dosage. Middle Aged. Prospective Studies. Protein Precursors / blood. Triiodothyronine / administration & dosage. Tumor Necrosis Factor-alpha / blood

  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • Hazardous Substances Data Bank. Calcitonin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696643.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / /
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Biomarkers; 0 / IL6 protein, human; 0 / Inflammation Mediators; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Protein Precursors; 0 / Tumor Necrosis Factor-alpha; 06LU7C9H1V / Triiodothyronine; 56645-65-9 / procalcitonin; 9007-12-9 / Calcitonin; 9007-41-4 / C-Reactive Protein; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


28. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer; 2005 Dec 15;104(12):2862-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: High-grade astrocytomas (HGA) carry a dismal prognosis and compose nearly 20% of all childhood brain tumors.
  • The authors conclude that these commonly used HDCT regimens provide no additional clinical benefit to conventional treatment in HGA, regardless of the amount of measurable residual tumor.
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Reference Values. Risk Assessment. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16315242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


29. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, Alberta JA, Bachoo RM, Kane M, Louis DN, Depinho RA, Anderson DJ, Stiles CD, Rowitch DH: Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron; 2007 Feb 15;53(4):503-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.
  • Recent studies have identified stem cells in brain cancer.
  • We observe expression of the CNS-restricted transcription factor, OLIG2, in human glioma stem and progenitor cells reminiscent of type C transit-amplifying cells in germinal zones of the adult brain.
  • Moreover, we show p21(WAF1/CIP1), a tumor suppressor and inhibitor of stem cell proliferation, is directly repressed by OLIG2 in neural progenitors and gliomas.
  • Our findings identify an Olig2-regulated lineage-restricted pathway critical for proliferation of normal and tumorigenic CNS stem cells.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Jul 26;26(30):7907-18 [16870736.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Nature. 2006 Sep 28;443(7110):448-52 [16957738.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Genes Dev. 2004 Mar 15;18(6):629-40 [15075291.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1804-8 [10710306.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 [14575240.001]
  • [Cites] Neuron. 2003 Oct 30;40(3):485-99 [14642274.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1374-9 [14734810.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Feb;63(2):170-9 [14989603.001]
  • [Cites] Development. 2004 Mar;131(6):1289-98 [14960493.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):499-509 [15198128.001]
  • [Cites] Science. 2004 Sep 3;305(5689):1466-70 [15353804.001]
  • [Cites] J Cell Biol. 2004 Sep 27;166(7):963-8 [15452140.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Brain Res. 1972 Aug 25;43(2):429-35 [4559710.001]
  • [Cites] Cancer Res. 1988 Oct 1;48(19):5433-9 [3416300.001]
  • [Cites] Cell. 2002 Apr 5;109(1):61-73 [11955447.001]
  • [Cites] Cell. 2002 Apr 5;109(1):75-86 [11955448.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):125-8 [12086870.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):269-77 [12086863.001]
  • [Cites] Curr Biol. 2002 Jul 9;12(13):1157-63 [12121626.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):143-9 [12241107.001]
  • [Cites] Science. 2002 Oct 18;298(5593):597-600 [12228720.001]
  • [Cites] Science. 2002 Oct 18;298(5593):601-4 [12228721.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Neurosci. 2003 Oct 22;23(29):9547-56 [14573534.001]
  • [Cites] Neuron. 1997 Apr;18(4):553-62 [9136765.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4187-90 [9331072.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2259-64 [9619835.001]
  • [Cites] Curr Opin Cell Biol. 1998 Dec;10(6):791-7 [9914179.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2963-72 [15574597.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2111-5 [15604411.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):565-76 [15607961.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D91-7 [15608292.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2883 [15625347.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):282-94 [15655114.001]
  • [Cites] J Neurosci. 2005 Feb 9;25(6):1354-65 [15703389.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):756-67 [15769947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3980-5 [15899785.001]
  • [Cites] BMC Bioinformatics. 2005;6:79 [15799782.001]
  • [Cites] Exp Neurol. 2005 Aug;194(2):320-32 [15992799.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Nat Neurosci. 2005 Jul;8(7):865-72 [15951811.001]
  • [Cites] Development. 2006 Jan;133(2):363-9 [16368933.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1433-41 [16554441.001]
  • [Cites] Dev Biol. 2006 May 15;293(2):348-57 [16537079.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7853-8 [16682644.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3587-96 [2194165.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] Science. 1996 Mar 29;271(5257):1861-4 [8596954.001]
  • [Cites] Mol Cell Biol. 1996 Aug;16(8):4327-36 [8754833.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):17-23 [9049826.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 [10737801.001]
  • [Cites] Neuron. 2001 Apr;30(1):19-35 [11343642.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] J Neurooncol. 2001 Feb;51(3):245-64 [11407596.001]
  • [Cites] Lancet. 2001 Jul 28;358(9278):298-300 [11498220.001]
  • [Cites] J Neurooncol. 2001 May;52(3):263-72 [11519857.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6 [11526205.001]
  • [Cites] Neuron. 2001 Sep 13;31(5):757-71 [11567615.001]
  • [Cites] Neuron. 2001 Sep 13;31(5):773-89 [11567616.001]
  • [Cites] Nat Neurosci. 2001 Oct;4(10):973-4 [11574831.001]
  • [Cites] Clin Immunol. 2002 Jan;102(1):84-95 [11781071.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):601-10 [11931767.001]
  • [Cites] Methods Mol Biol. 2002;198:15-27 [11951618.001]
  • [Cites] Neuron. 2006 Jul 20;51(2):151-3 [16846849.001]
  • [Cites] Neuron. 2006 Jul 20;51(2):187-99 [16846854.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • (PMID = 17296553.001).
  • [ISSN] 1097-4199
  • [Journal-full-title] Neuron
  • [ISO-abbreviation] Neuron
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS040511; United States / NINDS NIH HHS / NS / K08NS047213; United States / NINDS NIH HHS / NS / NS05563; United States / NCI NIH HHS / CA / P01 CA095616; United States / NINDS NIH HHS / NS / F32 NS055631; United States / NCI NIH HHS / CA / P01 CA95616; United States / NINDS NIH HHS / NS / P01 NS047572; United States / Howard Hughes Medical Institute / / ; United States / NINDS NIH HHS / NS / P01NS047572; United States / NINDS NIH HHS / NS / R01NS40511; United States / NINDS NIH HHS / NS / K08 NS047213
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Nerve Tissue Proteins; 0 / Olig2 protein, mouse; 147336-22-9 / Green Fluorescent Proteins; EC 1.13.12.- / Luciferases; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ NIHMS18231; NLM/ PMC1810344
  •  go-up   go-down


30. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J: Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res; 2008;27:85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
  • AIM: Gliomas represent the most frequent neoplasm of the central nervous system.
  • Unfortunately, surgical cure of it is practically impossible and their clinical course is primarily determined by the biological behaviors of the tumor cells.
  • The aim of this study was to investigate the correlation of the stem cell markers Nestin and CD133 expression with the grading of gliomas, and to evaluate their prognostic value.
  • METHODS: The tissue samples consisted of 56 low- (WHO grade II), 69 high- (WHO grade III, IV) grade gliomas, and 10 normal brain tissues.
  • RESULTS: Immunohistochemical analysis with anti-Nestin and anti-CD133 antibodies revealed dense and spotty staining in the tumor cells and their expression levels became significantly higher as the glioma grade advanced (p < 0.05).
  • A combined detection of Nestin/CD133 co-expression may benefit us in the prediction of aggressive nature of this tumor.
  • [MeSH-major] Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Brain Neoplasms / metabolism. Glioma / metabolism. Glycoproteins / biosynthesis. Intermediate Filament Proteins / biosynthesis. Neoplastic Stem Cells / metabolism. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Nestin. Peptides. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Exp Neurol. 2000 Feb;161(2):585-96 [10686078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5 [11121071.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2387-95 [11489817.001]
  • [Cites] J Physiol Paris. 2002 Jan-Mar;96(1-2):81-90 [11755786.001]
  • [Cites] Exp Neurol. 2002 Mar;174(1):89-95 [11869037.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 May;4(3):228-33 [15102349.001]
  • [Cites] J Neurooncol. 2004 Jun;68(2):113-21 [15218947.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Radiother Oncol. 1991 Feb;20(2):99-110 [1851573.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 [9356465.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23(6):791-804 [15917475.001]
  • [Cites] BMC Cancer. 2006;6:32 [16457706.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):485-92 [16418842.001]
  • [Cites] Acta Neuropathol. 2006 Mar;111(3):272-7 [16538520.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):227-33 [16826367.001]
  • [Cites] Surg Neurol. 2007 Aug;68(2):133-43; discussion 143-4 [17537489.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6970-7 [18056172.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):467-73 [17873113.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):370-7 [18371181.001]
  • (PMID = 19108713.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Peptides
  • [Other-IDs] NLM/ PMC2633002
  •  go-up   go-down


31. Bacciu A, Piazza P, Di Lella F, Sanna M: Intracanalicular meningioma: clinical features, radiologic findings, and surgical management. Otol Neurotol; 2007 Apr;28(3):391-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to describe the clinical, radiologic, and histopathologic features of 13 intracanalicular meningiomas highlighting important aspects of tumor diagnosis and treatment.
  • RESULTS: Total tumor removal was achieved in all cases.
  • [MeSH-minor] Adolescent. Adult. Aged. Audiometry, Pure-Tone. Evoked Potentials, Auditory, Brain Stem. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Retrospective Studies

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287658.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Hyun SJ, Rhim SC, Riew KD: A combined posterior, lateral, and anterior approach to ventrolaterally situated chordoma of the upper cervical spine. Surg Neurol; 2009 Oct;72(4):409-13; discussion 413
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional direct posterior approaches sometimes may not allow adequate visualization of the entire tumor base without significant manipulation of the brain stem and spinal cord.
  • Neuroradiologic examination revealed an osseous tumor at the C2-3 level that presented with severe spinal cord compression and considerable bone destruction.
  • We performed a resection of the tumor and posterior screw fixation from occiput to C5 using a conventional direct posterior approach.
  • However, we were unable to reach a part of the tumor that extended far laterally to the left side with VA involvement.
  • To expose and resect this remaining tumor, we used a far-lateral approach just posterior to the SCM muscle.
  • Resecting the transverse processes of C2 and C3 and mobilizing the V2 segment of the VA adequately exposed the tumor for resection.
  • After resection of the remaining posterior-lateral tumor, we closed and made the final approach anteriorly to resect the anterior tumor via an anterior corpectomy and fusion.
  • [MeSH-minor] Adult. Axis, Cervical Vertebra / pathology. Axis, Cervical Vertebra / radiography. Axis, Cervical Vertebra / surgery. Craniotomy / methods. Decompression, Surgical / methods. Epidural Space / pathology. Epidural Space / radiography. Epidural Space / surgery. Humans. Laminectomy / methods. Male. Occipital Bone / anatomy & histology. Occipital Bone / surgery. Postoperative Complications / prevention & control. Quadriplegia / etiology. Quadriplegia / physiopathology. Spinal Canal / pathology. Spinal Canal / radiography. Spinal Canal / surgery. Spinal Cord Compression / etiology. Spinal Cord Compression / pathology. Spinal Cord Compression / surgery. Spinal Fusion / methods. Treatment Outcome. Vertebroplasty / methods


33. Piccirillo E, Hiraumi H, Hamada M, Russo A, De Stefano A, Sanna M: Intraoperative cochlear nerve monitoring in vestibular schwannoma surgery--does it really affect hearing outcome? Audiol Neurootol; 2008;13(1):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among these, 99 patients with preoperative normal and social hearing (class A and B in the modified Sanna classification) and with a small tumor <1.5 cm in size were included in the analysis.
  • [MeSH-minor] Action Potentials. Adult. Aged. Cochlear Nerve / physiology. Cranial Fossa, Middle / surgery. Evoked Potentials, Auditory, Brain Stem. Female. Hearing. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 S. Karger AG, Basel.
  • (PMID = 17890858.001).
  • [ISSN] 1421-9700
  • [Journal-full-title] Audiology & neuro-otology
  • [ISO-abbreviation] Audiol. Neurootol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


34. Katoh Y, Katoh M: Comparative integromics on FAT1, FAT2, FAT3 and FAT4. Int J Mol Med; 2006 Sep;18(3):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FAT1 mRNA was expressed in embryonic stem (ES) cells, neural tissues, gastric cancer, pancreatic cancer, colorectal cancer, breast cancer, lung cancer and brain tumors.
  • FAT2 mRNA was expressed in infant brain, cerebellum, gastric cancer, pancreatic cancer, ovarian cancer, esophageal cancer, skin squamous cell carcinoma, head and neck cancer.
  • FAT3 mRNA was expressed in ES cells, primitive neuroectoderm, fetal brain, infant brain, adult neural tissues and prostate.
  • FAT4 mRNA was expressed in fetal brain, infant brain, brain tumor and colorectal cancer.

  • Genetics Home Reference. consumer health - FAT4 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16865240.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / FAT2 protein, human; 0 / FAT3 protein, human; 0 / Fat4 protein, mouse; 0 / Fath protein, mouse; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


35. Medhkour A, Chan M: Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature. Surg Neurol; 2005 Jun;63(6):576-82; discussion 582-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely rare glioblastoma multiforme of the conus medullaris with holocord and brain stem metastases, leading to cranial nerve deficit and respiratory failure: a case report and review of the literature.
  • Proper diagnosis via histopathologic and immunochemical staining with close clinical and radiological follow-up is important for the management of this very aggressive tumor.
  • CASE DESCRIPTION: The authors report the clinical features, histopathologic and immunochemical staining characteristics, as well as the radiographic evidence of a case of primary GBM of the conus medullaris with metastases to the whole spinal cord and brain in a 20-year-old man who presented with low back pain and bilateral lower extremity weakness and numbness.
  • Serial magnetic resonance scans, performed after the initial surgery, demonstrated enlargement of the primary GBM in the conus medullaris with metastases to the thoracic and cervical spinal cord as well as to the brain.
  • [MeSH-major] Brain Stem Neoplasms / secondary. Glioblastoma / secondary. Spinal Cord Compression / pathology. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / physiopathology. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Cranial Nerve Diseases / physiopathology. Disease Progression. Fatal Outcome. Glial Fibrillary Acidic Protein / metabolism. Humans. Low Back Pain / etiology. Low Back Pain / pathology. Low Back Pain / physiopathology. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Paresis / etiology. Paresis / pathology. Paresis / physiopathology. Rare Diseases. Respiratory Insufficiency / etiology. Respiratory Insufficiency / pathology. Respiratory Insufficiency / physiopathology. Spinal Cord / pathology. Spinal Cord / physiopathology

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936395.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 13
  •  go-up   go-down


36. Giussani C, Poliakov A, Ferri RT, Plawner LL, Browd SR, Shaw DW, Filardi TZ, Hoeppner C, Geyer JR, Olson JM, Douglas JG, Villavicencio EH, Ellenbogen RG, Ojemann JG: DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. Neuroimage; 2010 Aug 1;52(1):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma.
  • OBJECT: Intrinsic diffuse brainstem tumors and demyelinating diseases primarily affecting the brainstem can share common clinical and radiological features, sometimes making the diagnosis difficult especially at the time of first clinical presentation.
  • To explore the potential usefulness of new MRI sequences in particular diffusion tensor imaging fiber tracking in differentiating these two pathological entities, we review a series of brainstem tumors and demyelinating diseases treated at our institution.
  • MATERIAL AND METHODS: The clinical history including signs and symptoms and MRI findings of three consecutive demyelinating diseases involving the brainstem that presented with diagnostic uncertainty and three diffuse intrinsic brainstem tumors were reviewed, along with a child with a supratentorial tumor for comparison.
  • RESULTS: Routine MR imaging was unhelpful in differentiating between intrinsic tumor and demyelination.
  • In contrast, retrospective DTI fiber tracking clearly differentiated the pathology showing deflection of the pyramidal tracts posteriorly and laterally in the case of intrinsic brainstem tumors and, in the case of demyelinating disease, poorly represented and truncated fibers.
  • CONCLUSION: DTI fiber tracking of the pyramid tracts in patients with suspected intrinsic brainstem tumor or demyelinating disease presents two clearly different patterns that may help in differentiating between these two pathologies when conventional MRI and clinical data are inconclusive.
  • [MeSH-major] Brain Diseases / pathology. Brain Stem Neoplasms / pathology. Demyelinating Diseases / pathology. Diagnosis, Computer-Assisted / methods. Diffusion Tensor Imaging / methods. Glioma / pathology
  • [MeSH-minor] Adolescent. Brain Stem / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging / methods. Male. Pyramidal Tracts / pathology. Retrospective Studies. Supratentorial Neoplasms / diagnosis. Supratentorial Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Demyelinating Diseases.
  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20363335.001).
  • [ISSN] 1095-9572
  • [Journal-full-title] NeuroImage
  • [ISO-abbreviation] Neuroimage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Salomoni P: Stemming out of a new PML era? Cell Death Differ; 2009 Aug;16(8):1083-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, it has been shown that PML is one of the key cell-cycle regulators controlling stem cell function in multiple tissues, from the blood to the brain.
  • As a consequence, PML loss has an impact on tissue development and maintenance of stem cell pools.
  • In addition, new data suggest that PML regulates self-renewal in cancer stem cells.
  • Finally, the oncogenic fusion protein PML/RARalpha, contrary to the conventional view, appears to hijack growth-suppressive pathways to promote transformation of haematopoietic stem cells and to maintain the APL stem cell niche.
  • Overall, these findings not only represent a change in paradigm in the field of PML/APL research, but also contribute to the understanding of fundamental mechanisms underlying stem cell function in vivo.
  • The main objective of this review is to critically discuss the very recent literature on the role of PML in stem cells and tumour-initiating cells.
  • [MeSH-major] Nuclear Proteins / physiology. Transcription Factors / physiology. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Adult Stem Cells / cytology. Animals. Antigen-Presenting Cells / cytology. Cell Cycle. Cell Differentiation. Humans. Mammary Glands, Human / cytology. Mice

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19521423.001).
  • [ISSN] 1476-5403
  • [Journal-full-title] Cell death and differentiation
  • [ISO-abbreviation] Cell Death Differ.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Pml protein, mouse; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 95
  •  go-up   go-down


38. Park HJ, Kim JK, Jeon HM, Oh SY, Kim SH, Nam DH, Kim H: The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells. Mol Cells; 2010 Nov;30(5):403-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neural stem cell fate determinant TLX promotes tumorigenesis and genesis of cells resembling glioma stem cells.
  • A growing body of evidence indicates that deregulation of stem cell fate determinants is a hallmark of many types of malignancies.
  • The neural stem cell fate determinant TLX plays a pivotal role in neurogenesis in the adult brain by maintaining neural stem cells.
  • Here, we report a tumorigenic role of TLX in brain tumor initiation and progression.
  • Increased TLX expression was observed in a number of glioma cells and glioma stem cells, and correlated with poor survival of patients with gliomas.
  • Ectopic expression of TLX in the U87MG glioma cell line and Ink4a/Arf-deficient mouse astrocytes (Ink4a/Arf(-/-) astrocytes) induced cell proliferation with a concomitant increase in cyclin D expression, and accelerated foci formation in soft agar and tumor formation in in vivo transplantation assays.
  • Furthermore, overexpression of TLX in Ink4a/Arf(-/-) astrocytes inhibited cell migration and invasion and promoted neurosphere formation and Nestin expression, which are hallmark characteristics of glioma stem cells, under stem cell culture conditions.
  • Our results indicate that TLX is involved in glioma stem cell genesis and represents a potential therapeutic target for this type of malignancy.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Glioma / pathology. Neoplastic Stem Cells / pathology. Neural Stem Cells / pathology. Receptors, Cytoplasmic and Nuclear / physiology
  • [MeSH-minor] Adult. Animals. Astrocytes / metabolism. Astrocytes / pathology. Astrocytoma / genetics. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Central Nervous System Neoplasms. Cyclin D / genetics. Humans. Intermediate Filament Proteins / genetics. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Metastasis. Nerve Tissue Proteins / genetics. Nestin. Neurogenesis. Prognosis. Up-Regulation

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mol Cells. 2011 Feb ;31(2):199. Park, Myung-Jin [removed]; Soeda, Akio [removed]
  • (PMID = 20814749.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / NR2E1 protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Cytoplasmic and Nuclear
  •  go-up   go-down


39. Erlich SA, Tymianski M, Kiehl TR: Cellular schwannoma of the abducens nerve: case report and review of the literature. Clin Neurol Neurosurg; 2009 Jun;111(5):467-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the case of a 26-year-old woman who presented with a 6th nerve palsy and was found to have a large tumor at the right side of her pons.
  • [MeSH-minor] Adult. Brain Stem Neoplasms / pathology. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neurosurgical Procedures. Paralysis. Pons / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Schwannoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200646.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Sakurada K, Saino M, Mouri W, Sato A, Kitanaka C, Kayama T: Nestin expression in central nervous system germ cell tumors. Neurosurg Rev; 2008 Apr;31(2):173-6; discussion 176-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nestin is an intermediate filament protein expressed in undifferentiated cells during CNS development and in CNS tumors and is used as a marker of immature elements of tumors, including brain tumor stem cells.
  • In this study, we examined for the first time nestin expression in 19 CNS germ cell tumors (nine pure germinomas, five germinomas with syncytiotrophoblastic giant cells, one yolk sac tumor, one choriocarcinoma, one embryonal carcinoma, and two mature teratomas).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Central Nervous System Neoplasms / genetics. Intermediate Filament Proteins / biosynthesis. Intermediate Filament Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Nerve Tissue Proteins / biosynthesis. Nerve Tissue Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Choriocarcinoma / genetics. Choriocarcinoma / metabolism. Choriocarcinoma / pathology. Endodermal Sinus Tumor / genetics. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Female. Germinoma / genetics. Germinoma / metabolism. Germinoma / pathology. Giant Cell Tumors / genetics. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Hypopituitarism / etiology. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Nestin. Teratoma / genetics. Teratoma / metabolism. Teratoma / pathology. Vision Disorders / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2510-22 [15526158.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):222-3 [15677549.001]
  • [Cites] APMIS. 2002 Jun;110(6):499-507 [12193211.001]
  • [Cites] Neurosci Lett. 2006 May 29;400(1-2):80-5 [16529857.001]
  • [Cites] Neurosurg Focus. 1998 Jul 15;5(1):e7 [17140188.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Neurol Res. 1989 Jun;11(2):118-26 [2569683.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6 [14711994.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):311-6 [11767296.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • (PMID = 18092184.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


41. Jin W, Ni H, Dai Y, Wang H, Lu T, Wu J, Jiang J, Liang W: Effects of tert-butylhydroquinone on intestinal inflammatory response and apoptosis following traumatic brain injury in mice. Mediators Inflamm; 2010;2010:502564
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of tert-butylhydroquinone on intestinal inflammatory response and apoptosis following traumatic brain injury in mice.
  • Traumatic brain injury (TBI) can induce intestinal inflammatory response and mucosal injury.
  • Adult male ICR mice were randomly divided into three groups:.
  • Intestinal mucosa apoptosis and inflammatory-related factors, such as nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1), were investigated at 24 h after TBI.
  • [MeSH-major] Apoptosis / drug effects. Brain Injuries. Hydroquinones / pharmacology. Inflammation. Intestinal Mucosa. Intestines

  • Hazardous Substances Data Bank. T-BUTYLHYDROQUINONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2005 Feb 28;11(8):1149-54 [15754395.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22925-36 [15840590.001]
  • [Cites] J Exp Med. 2005 Jul 4;202(1):47-59 [15998787.001]
  • [Cites] J Neurosci. 2005 Nov 2;25(44):10321-35 [16267240.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):984-95 [16585964.001]
  • [Cites] Arch Biochem Biophys. 2006 Oct 1;454(1):7-15 [16962985.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11580-4 [17178849.001]
  • [Cites] Cytokine. 2008 Oct;44(1):135-40 [18722136.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Mar 13;380(3):449-53 [19174151.001]
  • [Cites] J Neurotrauma. 2009 Jan;26(1):131-9 [19125683.001]
  • [Cites] J Surg Res. 2009 Dec;157(2):251-60 [19394962.001]
  • [Cites] Biochem Pharmacol. 2010 Jul 1;80(1):144-9 [20223225.001]
  • [Cites] Biosci Biotechnol Biochem. 2000 Jun;64(6):1153-8 [10923784.001]
  • [Cites] Drug Metab Dispos. 2000 Sep;28(9):1018-23 [10950843.001]
  • [Cites] Neurol Res. 2001 Mar-Apr;23(2-3):227-36 [11320604.001]
  • [Cites] J Neurochem. 2002 Jun;81(6):1233-41 [12068071.001]
  • [Cites] Burns. 2002 Dec;28(8):731-7 [12464470.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12029-38 [12556532.001]
  • [Cites] Biochemistry. 2003 Apr 15;42(14):4300-9 [12680784.001]
  • [Cites] Biochem Pharmacol. 2003 Sep 1;66(5):841-7 [12948865.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2776-81 [14669332.001]
  • [Cites] J Neurosci. 2004 Feb 4;24(5):1101-12 [14762128.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1721-5 [15073044.001]
  • [Cites] J Biochem Mol Biol. 2004 Mar 31;37(2):139-43 [15469687.001]
  • [Cites] Brain Res. 2004 Nov 5;1026(1):23-32 [15476694.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):882-7 [3998840.001]
  • [Cites] Nat Med. 1996 Sep;2(9):998-1004 [8782457.001]
  • [Cites] Stem Cells. 1997;15(2):82-93 [9090784.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22 [9240432.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Aug;158(2):444-51 [9700119.001]
  • [Cites] Clin Chem. 1999 Jan;45(1):7-17 [9895331.001]
  • [Cites] World Health Organ Tech Rep Ser. 1999;884:i-viii, 1-96 [10079756.001]
  • [Cites] J Neurotrauma. 1999 May;16(5):365-76 [10369557.001]
  • [Cites] J Clin Invest. 2004 Nov;114(9):1248-59 [15520857.001]
  • [Cites] Trends Mol Med. 2004 Nov;10(11):549-57 [15519281.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):244-9 [15611470.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):313-28 [15525690.001]
  • [Cites] J Surg Res. 2005 Feb;123(2):188-93 [15680377.001]
  • (PMID = 21274455.001).
  • [ISSN] 1466-1861
  • [Journal-full-title] Mediators of inflammation
  • [ISO-abbreviation] Mediators Inflamm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hydroquinones; 0 / NF-E2-Related Factor 2; 0 / NF-kappa B; 126547-89-5 / Intercellular Adhesion Molecule-1; C12674942B / 2-tert-butylhydroquinone
  • [Other-IDs] NLM/ PMC3025385
  •  go-up   go-down


42. Chamuleau RA, Deurholt T, Hoekstra R: Which are the right cells to be used in a bioartificial liver? Metab Brain Dis; 2005 Dec;20(4):327-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sources for the development of such human cell lines are liver-tumor-derived cell lines, immortalized fetal or adult hepatocytes, and stem cells of hepatic, hematopoietic, or embryonic origin.
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Fetus / cytology. Hematopoietic Stem Cells / physiology. Hepatocytes / physiology. Humans. Stem Cell Transplantation

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 30;425(6961):968-73 [14555960.001]
  • [Cites] Cell Transplant. 2003;12(5):469-73 [12953920.001]
  • [Cites] Hepatology. 1996 Dec;24(6):1446-51 [8938179.001]
  • [Cites] Diabetes. 2004 Jan;53(1):105-12 [14693704.001]
  • [Cites] Surgery. 2002 Aug;132(2):384-90 [12219039.001]
  • [Cites] Fukuoka Igaku Zasshi. 2001 Aug;92(8):299-305 [11586514.001]
  • [Cites] Hepatology. 1989 Mar;9(3):367-72 [2563984.001]
  • [Cites] Int J Artif Organs. 1999 Nov;22(11):769-77 [10612305.001]
  • [Cites] Nat Med. 2004 Jan;10(1):55-63 [14702635.001]
  • [Cites] Science. 2000 Feb 18;287(5456):1258-62 [10678831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11307-12 [11027332.001]
  • [Cites] Ann Surg. 2004 May;239(5):660-7; discussion 667-70 [15082970.001]
  • [Cites] Lancet. 2000 Aug 19;356(9230):621-7 [10968434.001]
  • [Cites] Mech Dev. 2003 Jan;120(1):117-30 [12490302.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1147-56 [15057753.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1229-34 [11062533.001]
  • [Cites] Int J Artif Organs. 2002 Oct;25(10):1001-5 [12456042.001]
  • [Cites] Liver Transpl. 2001 Jan;7(1):2-10 [11150414.001]
  • [Cites] Nat Med. 2004 Jul;10(7):744-8 [15195088.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):59-67 [8024360.001]
  • [Cites] Hepatology. 2000 Jul;32(1):11-6 [10869283.001]
  • [Cites] J Clin Invest. 2002 May;109(10):1291-302 [12021244.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):216-30 [15273544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jan;85(1):160-4 [2893372.001]
  • [Cites] Transplant Proc. 2001 Feb-Mar;33(1-2):1935 [11267578.001]
  • [Cites] Dev Dyn. 2004 Feb;229(2):243-58 [14745950.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):432-44 [12557149.001]
  • [Cites] ASAIO J. 1993 Jul-Sep;39(3):M242-6 [8268536.001]
  • [Cites] Int J Artif Organs. 1997 Aug;20(8):418-21 [9323503.001]
  • [Cites] Tissue Eng. 2004 Jul-Aug;10(7-8):1113-24 [15363168.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] Science. 1999 May 14;284(5417):1168-70 [10325227.001]
  • [Cites] J Hepatol. 1997 Jun;26(6):1379-92 [9210627.001]
  • [Cites] Transplant Proc. 1997 Feb-Mar;29(1-2):964-5 [9123610.001]
  • [Cites] Nature. 2000 Jul 20;406(6793):257 [10917519.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1891-900 [12806622.001]
  • [Cites] Cell Transplant. 2004;13(3):197-211 [15191158.001]
  • [Cites] Cell Transplant. 2001;10(4-5):429-33 [11549067.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):971-4 [11581665.001]
  • [Cites] Science. 1999 Aug 20;285(5431):1236-41 [10455044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3639-44 [11904425.001]
  • [Cites] Int J Artif Organs. 2002 Mar;25(3):182-91 [11999190.001]
  • (PMID = 16382343.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


43. Lee RH, Seo MJ, Pulin AA, Gregory CA, Ylostalo J, Prockop DJ: The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood; 2009 Jan 22;113(4):816-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We screened for surface proteins expressed only by the early progenitor cells present in low-passage, low-density cultures of the adult stem/progenitor cells from bone marrow referred to as mesenchymal stem cells or multipotent stromal cells (MSCs).
  • All were previously shown to be involved in cell trafficking or tumor progression.


44. Broniscer A, Laningham FH, Kocak M, Krasin MJ, Fouladi M, Merchant TE, Kun LE, Boyett JM, Gajjar A: Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer; 2006 Mar 15;106(6):1364-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.
  • BACKGROUND: Children with diffuse brainstem glioma (BSG) commonly undergo novel therapies because their outcome is poor with radiation therapy (RT).
  • METHODS: All available brain imaging studies and medical records of 48 consecutive patients with newly diagnosed BSG treated at the study institution over a 10-year interval (1992-2002) were reviewed.
  • At the time of last follow-up, all patients had died of tumor progression.
  • The uniform occurrence of IH among patients treated with various chemotherapeutic regimens and its association with necrotic areas suggests that tumor biology plays a significant role in this event.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Cerebral Hemorrhage / diagnosis. Glioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Female. Humans. Magnetic Resonance Imaging. Male. Necrosis. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16463390.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Gheri CF, Buccoliero AM, Pansini G, Castiglione F, Garbini F, Moncini D, Maccari C, Mennonna P, Pellicanò G, Ammannati F, Taddei GL: Lipoastrocytoma: Case report and review of the literature. Neuropathology; 2010 Oct;30(5):553-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoastrocytoma is an extremely rare tumor, with only six cases described.
  • We report the case of an astrocytoma involving the upper part of the cerebellar-pontine angle and the right portion of the clivus starting from the brainstem with a diffuse lipomatous component in a 39 year-old man.
  • Subtotal excision of the tumor was accomplished.
  • Histologically the tumor showed the classical histology of low-grade astrocytoma and a portion of the lesion was composed of lipid-laden cells.
  • It is important to record each new case of this rare tumor to produce a better characterization of this lesion.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Lipomatosis / pathology
  • [MeSH-minor] Adult. Brain Stem / pathology. Cerebellum / pathology. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Society of Neuropathology.
  • (PMID = 20113404.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Keywords] NOTNLM ; lipid vacuole / lipoastrocytoma / lipomatous / low grade astrocytoma
  •  go-up   go-down


46. Pistollato F, Abbadi S, Rampazzo E, Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D'avella D, Basso G: Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells; 2010 May;28(5):851-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
  • Our results indicate that more immature cells are localized in the inner core and in the intermediate layer of the tumor mass, whereas more committed cells, expressing glial fibrillary acidic protein and beta-III-tubulin, are distributed along the peripheral and neo-vascularized area, where Smad1/5/8 and Stat3 result to be activated.
  • Moreover, GBM stem cells, identified with the stem cell marker CD133, express high level of DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT) known to be involved in chemotherapy resistance and highly expressed in the inner core of the tumor mass.
  • Importantly, these cells and, particularly, CD133(+) cells result to be resistant to temozolomide (TMZ), the most used oral alkylating agent for the treatment of GBM, which specifically causes apoptosis only in GBM cells derived from the peripheral layer of the tumor mass.
  • These results indicate a correlation between the intratumoral hypoxic gradient, the tumor cell phenotype, and the tumor resistance to chemotherapy leading to a novel concentric model of tumor stem cell niche, which may be useful to define the real localization of the chemoresistant GBM tumor cells in order to design more effective treatment strategies.
  • [MeSH-major] Anoxia / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. DNA Modification Methylases / biosynthesis. DNA Repair Enzymes / biosynthesis. Glioblastoma / metabolism. Glioblastoma / pathology. Neoplastic Stem Cells / metabolism. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Cell Dedifferentiation / physiology. Glycoproteins / metabolism. Humans. Infant, Newborn. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Peptides / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20309962.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


47. Demeter K, Zádori A, Agoston VA, Madarász E: Studies on the use of NE-4C embryonic neuroectodermal stem cells for targeting brain tumour. Neurosci Res; 2005 Nov;53(3):331-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on the use of NE-4C embryonic neuroectodermal stem cells for targeting brain tumour.
  • Neural stem cells were suggested to migrate to and invade intracranial gliomas.
  • In the presented studies, interactions of NE-4C embryonic neural stem cells were investigated with C6 and Gl261, LL and U87, glioblastoma cells or with primary astrocytes.
  • Glioma-derived humoral factors did not influence the proliferation of stem cells.
  • In chimera-aggregates, all types of glioma cells co-aggregated with astrocytes, but most of them segregated from stem cells.
  • Complete intercalation of stem and tumour cells was detected only in chimera-aggregates of Gl261 glioma and NE-4C cells.
  • If mixed suspensions of NE-4C and Gl261 cells were injected into the brain, stem cells survived and grew inside the tumour mass.
  • NE-4C stem cells, however, did not migrate towards the tumour, if implanted near to Gl261 tumours established in the adult mouse forebrain.
  • The observations indicate that not all types of stem cells could be used for targeting all sorts of brain tumours.
  • [MeSH-major] Brain Neoplasms / therapy. Brain Tissue Transplantation / methods. Ectoderm / transplantation. Stem Cell Transplantation / methods. Stem Cells / physiology
  • [MeSH-minor] Animals. Astrocytes / physiology. Cell Aggregation / physiology. Cell Communication / physiology. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Cell Movement / physiology. Cell Proliferation / drug effects. Coculture Techniques. Glioblastoma / physiopathology. Glioblastoma / therapy. Graft Survival / physiology. Growth Substances / metabolism. Growth Substances / pharmacology. Humans. Mice. Neoplasm Invasiveness / physiopathology. Rats

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16183159.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Growth Substances
  •  go-up   go-down


48. Gorgulho A, De Salles AA, McArthur D, Agazaryan N, Medin P, Solberg T, Mattozo C, Ford J, Lee S, Selch MT: Brainstem and trigeminal nerve changes after radiosurgery for trigeminal pain. Surg Neurol; 2006 Aug;66(2):127-35; discussion 135
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem and trigeminal nerve changes after radiosurgery for trigeminal pain.
  • Twenty-nine had ETN, 5 secondary TN due to tumor or multiple sclerosis, and 3 had atypical TN.
  • Enhancement on MRIs was observed in 21 cases (56.75%) with nerve enhancement in 9, pons enhancement in 4, pons-nerve enhancement in 4, and tumor enhancement in 4.
  • Paresthesias correlated with enhancement (P = .02), but not with brainstem volume encompassed by the 20%, 30%, and 50% isodoseline (P = .689, .525, .908).
  • Radiation delivery to the brainstem-REZ interface seems to improve pain outcome, although more paresthesias should be expected.
  • [MeSH-major] Brain Stem / pathology. Radiosurgery. Trigeminal Nerve / pathology. Trigeminal Neuralgia / pathology. Trigeminal Neuralgia / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Paresthesia / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876597.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Santagata S, Hornick JL, Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol; 2006 Dec;30(12):1613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The homeodomain transcription factor, NANOG, along with OCT3/4 (POU5F1) and SOX2, is part of the core set of transcription factors that maintain embryonic stem cell self-renewal and pluripotency.
  • To assess the diagnostic utility of NANOG in central nervous system (CNS) germ cell tumors, we analyzed its expression by immunohistochemistry in a series of 12 CNS germinomas and compared its expression with other stem cell markers.
  • Strong nuclear expression of NANOG was demonstrated in >90% of the tumor cells in all cases.
  • NANOG was not detected in tumor types frequently considered in the differential diagnosis of CNS germinoma: pineoblastoma, primitive neuroectodermal tumors, medulloblastoma, lymphoma, pituitary adenoma, atypical teratoid/rhabdoid tumor, Langerhans cell histiocytosis, and gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / metabolism. Germinoma / metabolism. Homeodomain Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase / metabolism. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Child. HMGB Proteins / metabolism. Humans. Isoenzymes / metabolism. Octamer Transcription Factor-3 / metabolism. SOXB1 Transcription Factors. Transcription Factors / metabolism

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122519.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047213
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / HMGB Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / germ-cell AP isoenzyme; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


50. Cui JG, Zhao Y, Sethi P, Li YY, Mahta A, Culicchia F, Lukiw WJ: Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. J Neurooncol; 2010 Jul;98(3):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation.
  • High density micro-RNA (miRNA) arrays, fluorescent-reporter miRNA assay and Northern miRNA dot-blot analysis show that a brain-enriched miRNA-128 is significantly down-regulated in glioblastoma multiforme (GBM) and in GBM cell lines when compared to age-matched controls.
  • The down-regulation of miRNA-128 was found to inversely correlate with WHO tumor grade.
  • Three bioinformatics-verified miRNA-128 targets, angiopoietin-related growth factor protein 5 (ARP5; ANGPTL6), a transcription suppressor that promotes stem cell renewal and inhibits the expression of known tumor suppressor genes involved in senescence and differentiation, Bmi-1, and a transcription factor critical for the control of cell-cycle progression, E2F-3a, were found to be up-regulated.
  • [MeSH-major] Angiopoietins / metabolism. Brain / pathology. Brain Neoplasms / pathology. Cell Proliferation. Down-Regulation / physiology. E2F3 Transcription Factor / metabolism. Glioblastoma / pathology. MicroRNAs / metabolism. Nuclear Proteins / metabolism. Proto-Oncogene Proteins / metabolism. Repressor Proteins / metabolism
  • [MeSH-minor] Adult. Computational Biology / methods. Female. Humans. Male. Middle Aged. Polycomb Repressive Complex 1. RNA, Messenger / metabolism. Transfection / methods

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2009 Jan;91(1):27-32 [18759060.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8 [16039986.001]
  • [Cites] Mol Pharmacol. 2009 Feb;75(2):259-64 [19004981.001]
  • [Cites] Genes Dev. 2009 Mar 1;23 (5):561-74 [19270157.001]
  • [Cites] Genes Dev. 2001 Feb 15;15(4):386-91 [11230146.001]
  • [Cites] PLoS One. 2008;3(11):e3652 [18987751.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9125-30 [19010882.001]
  • [Cites] Biochemistry (Mosc). 2007 May;72(5):578-82 [17573714.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1627-30 [14716298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Mol Cell Biol. 2009 Jan;29(2):414-24 [19015245.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):325-32 [19159078.001]
  • [Cites] Methods Mol Biol. 2007;377:187-202 [17634618.001]
  • [Cites] J Mol Med (Berl). 2009 Jan;87(1):43-51 [18810376.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3415-23 [18202223.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Aug 14;386(1):1-5 [19523920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9494-9 [12871997.001]
  • [Cites] Neuroreport. 2007 Feb 12;18(3):297-300 [17314675.001]
  • [Cites] Neuroreport. 2008 Jun 11;19(9):981-5 [18521005.001]
  • [Cites] J Inorg Biochem. 2007 Sep;101(9):1265-9 [17629564.001]
  • [Cites] J Biol Chem. 2008 Nov 14;283(46):31315-22 [18801740.001]
  • [Cites] J Biomed Biotechnol. 2009;2009:871313 [19707536.001]
  • [Cites] Nat Genet. 2007 May;39(5):673-7 [17401365.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):599-611 [19343354.001]
  • [Cites] Neurosci Lett. 2009 Aug 7;459(2):100-4 [19406203.001]
  • (PMID = 19941032.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ANGPTL6 protein, human; 0 / Angiopoietins; 0 / BMI1 protein, human; 0 / E2F3 Transcription Factor; 0 / MIRN128 microRNA, human; 0 / MicroRNAs; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; EC 2.3.2.27 / Polycomb Repressive Complex 1
  •  go-up   go-down


51. Stark AM, Maslehaty H, Hugo HH, Mahvash M, Mehdorn HM: Glioblastoma of the cerebellum and brainstem. J Clin Neurosci; 2010 Oct;17(10):1248-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma of the cerebellum and brainstem.
  • Glioblastoma multiforme (GB) is the most common and most malignant primary intracranial tumor.
  • Because of its rarity and the non-specific radiological features of iGB, it can easily be misdiagnosed as a brain metastasis, ependymoma or even as a benign lesion such as vestibular schwannoma or meningioma.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Stem / pathology. Cerebellum / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20619657.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


52. Chabu C, Doe CQ: Twins/PP2A regulates aPKC to control neuroblast cell polarity and self-renewal. Dev Biol; 2009 Jun 15;330(2):399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Asymmetric cell division is a mechanism for generating cell diversity as well as maintaining stem cell homeostasis in both Drosophila and mammals.
  • In Drosophila, larval neuroblasts are stem cell-like progenitors that divide asymmetrically to generate neurons of the adult brain.
  • Cortical aPKC excludes cortical localization of Miranda and its cargo proteins Prospero and Brain tumor, resulting in their partitioning into the differentiating, smaller ganglion mother cell (GMC) where they are required for neuronal differentiation.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • FlyBase. FlyBase .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2001 Jan;3(1):43-9 [11146625.001]
  • [Cites] J Cell Biol. 2000 Sep 18;150(6):1361-74 [10995441.001]
  • [Cites] Cancer Lett. 2001 Sep 10;170(1):1-13 [11448528.001]
  • [Cites] Development. 2002 Jul;129(14):3493-503 [12091318.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):967-78 [12196510.001]
  • [Cites] Nat Cell Biol. 2003 Feb;5(2):166-70 [12545176.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):326-30 [12629552.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1089-98 [14657233.001]
  • [Cites] Cell. 2003 Dec 12;115(6):691-704 [14675534.001]
  • [Cites] Genes Dev. 1993 Mar;7(3):429-40 [8383623.001]
  • [Cites] Cell. 1994 Feb 11;76(3):477-91 [8313469.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):624-7 [7566172.001]
  • [Cites] J Cell Sci. 1996 Dec;109 ( Pt 13):3001-12 [9004035.001]
  • [Cites] Nature. 1997 Dec 11;390(6660):625-9 [9403694.001]
  • [Cites] Development. 1999 Sep;126(18):4065-76 [10457015.001]
  • [Cites] Mol Biol Cell. 2005 Nov;16(11):5127-40 [16107559.001]
  • [Cites] Nature. 2006 Feb 2;439(7076):594-8 [16357871.001]
  • [Cites] Cell. 2006 Mar 24;124(6):1241-53 [16564014.001]
  • [Cites] Dev Cell. 2006 Apr;10(4):441-9 [16549393.001]
  • [Cites] Development. 2006 Jul;133(14):2639-48 [16774999.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3453-63 [17182870.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3464-74 [17182871.001]
  • [Cites] Neural Dev. 2007;2:1 [17207270.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):624-35 [17475233.001]
  • [Cites] Nature. 2007 Sep 6;449(7158):96-100 [17805297.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3200-6 [17726059.001]
  • [Cites] Neural Dev. 2008;3:5 [18284664.001]
  • [Cites] Trends Biochem Sci. 2008 Mar;33(3):113-21 [18291659.001]
  • [Cites] Development. 2008 Apr;135(8):1471-80 [18339672.001]
  • [Cites] Development. 2008 May;135(9):1575-87 [18356248.001]
  • [Cites] Dev Cell. 2008 Apr;14(4):535-46 [18342578.001]
  • [Cites] Dev Neurobiol. 2008 Aug;68(9):1185-95 [18548484.001]
  • [Cites] Development. 2008 Aug;135(16):2739-46 [18614576.001]
  • [Cites] Fly (Austin). 2007 Jul-Aug;1(4):235-7 [18820442.001]
  • [Cites] Genes Dev. 2009 Feb 1;23(3):359-72 [19204120.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):544-7 [10591216.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):417-39 [11171037.001]
  • (PMID = 19374896.001).
  • [ISSN] 1095-564X
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD007348-21; United States / NICHD NIH HHS / HD / T32 HD007348; United States / NICHD NIH HHS / HD / T32 HD007348-21; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.16 / Protein Phosphatase 2
  • [Other-IDs] NLM/ NIHMS121355; NLM/ PMC2728501
  •  go-up   go-down


53. Wang W, Yang H, Hu W, Shan G, Ding W, Yu C, Wang B, Wang X, Xu Q: Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2010 Jun 1;77(2):617-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The IMRT was delivered in 33 fractions, to 70 to 76Gy, to the gross tumor volume (GTV).
  • [MeSH-minor] Adult. Aged. Brain Stem / radiation effects. Dose Fractionation. Female. Humans. Male. Middle Aged. Parotid Gland / radiation effects. Spinal Cord / radiation effects. Tumor Burden

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20138444.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Laigle-Donadey F, Doz F, Delattre JY: Brainstem gliomas in children and adults. Curr Opin Oncol; 2008 Nov;20(6):662-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem gliomas in children and adults.
  • PURPOSE OF REVIEW: The purpose of this review is to determine if recent advances in diagnostic and treatment modalities result in improvement in the pattern of care of brainstem gliomas.
  • RECENT FINDINGS: New MRI techniques may contribute to differential diagnosis and aid neurosurgeons in removing resectable brainstem tumors.
  • However, biopsy remains indicated in many contrast enhancing brainstem masses in adults because of the great variety of differential diagnosis.
  • SUMMARY: Diffuse brainstem glioma is the most common subtype of brainstem tumor and remains a devastating malignancy in children.
  • Given the lack of efficacy of conventional drugs, a better understanding of the biology of this tumor is the key to more targeted therapy.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Stem / pathology. Glioma / drug therapy
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Child. Drug Delivery Systems. Humans. Magnetic Resonance Imaging / methods. Medical Oncology / methods. Neoplasm Metastasis. Neurofibromatosis 1 / drug therapy. Neurofibromatosis 1 / pathology. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18841048.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents
  • [Number-of-references] 57
  •  go-up   go-down


55. Maza S, Kiewe P, Munz DL, Korfel A, Hamm B, Jahnke K, Thiel E: First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma. Neuro Oncol; 2009 Aug;11(4):423-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood-brain barrier after tumor shrinkage.
  • In six patients, biodistribution of the antibody was measured by indium-111 ((111)In) ibritumomab tiuxetan whole-body scans and single-photon-emission CT (SPECT) of the brain.
  • Because of limited response duration and considerable hematotoxicity, future investigations should focus on a multimodal approach with additional chemotherapy and preferably autologous stem cell support.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Central Nervous System Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Survival Rate. Tissue Distribution. Yttrium Radioisotopes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1999 Jul;43(3):249-57 [10563431.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2453-63 [12011122.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Eur J Cancer. 1991;27(11):1356-61 [1835848.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Eur J Haematol. 2005 Apr;74(4):348-52 [15777348.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1710-1 [15972281.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):53-8 [16283435.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Nov;7(3):236-8 [17229341.001]
  • [Cites] J Neurooncol. 2007 Jul;83(3):291-3 [17245621.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • (PMID = 19060176.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Other-IDs] NLM/ PMC2743222
  •  go-up   go-down


56. Malik AK, Khaldoyanidi S, Auci DL, Miller SC, Ahlem CN, Reading CL, Page T, Frincke JM: 5-Androstene-3β,7β,17β-triol (β-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis. PLoS One; 2010;5(10):e13566
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5-Androstene-3β,7β,17β-triol (β-AET), an active metabolite of dehydroepiandrosterone (DHEA), reversed glucocorticoid (GC)-induced suppression of IL-6, IL-8 and osteoprotegerin production by human osteoblast-like MG-63 cells and promoted osteoblast differentiation of human mesenchymal stem cells (MSCs).
  • [MeSH-minor] Absorptiometry, Photon. Adult. Aged. Aged, 80 and over. Animals. Cell Differentiation. Cell Line, Tumor. Female. Flow Cytometry. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged

  • Genetic Alliance. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes Care. 2008 May;31(5):845-51 [18223031.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):344-9 [18417338.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):223-9 [18513951.001]
  • [Cites] J Rheumatol. 2008 Aug;35(8):1567-75 [18634158.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Sep;4(9):507-13 [18695700.001]
  • [Cites] Pediatr Res. 2009 Feb;65(2):249-51 [19262295.001]
  • [Cites] Autoimmun Rev. 2009 Mar;8(5):369-72 [19071234.001]
  • [Cites] Bone. 2009 Jul;45(1):61-7 [19358901.001]
  • [Cites] Orthopedics. 2009 Aug;32(8). pii: orthosupersite.com/view.asp?rID=41933. doi: 10.3928/01477447-20090624-27 [19708622.001]
  • [Cites] J Pharmacol Exp Ther. 2010 Apr;333(1):70-80 [20068030.001]
  • [Cites] Clin Orthop Relat Res. 2010 Jul;468(7):1991-6 [20020334.001]
  • [Cites] Eur J Endocrinol. 2006 May;154(5):745-51 [16645023.001]
  • [Cites] J Clin Invest. 2004 Mar;113(6):846-55 [15067317.001]
  • [Cites] Steroids. 2004 Apr;69(4):279-89 [15183694.001]
  • [Cites] EMBO Rep. 2004 Oct;5(10):1007-12 [15359271.001]
  • [Cites] Proc Soc Exp Biol Med. 1991 Jan;196(1):8-16 [1824576.001]
  • [Cites] J Infect Dis. 1993 Apr;167(4):830-40 [8450248.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1544-52 [8046232.001]
  • [Cites] Blood. 1994 Dec 15;84(12):4116-24 [7527666.001]
  • [Cites] Cell. 1995 Feb 10;80(3):371-8 [7859279.001]
  • [Cites] Steroids. 1995 Jan;60(1):143-6 [7792800.001]
  • [Cites] Ann N Y Acad Sci. 1995 Dec 29;774:323-5 [8597477.001]
  • [Cites] J Endocrinol. 1996 Sep;150 Suppl:S209-20 [8943803.001]
  • [Cites] J Cell Biochem. 1997 Feb;64(2):278-94 [9027588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):4925-30 [9144166.001]
  • [Cites] Psychoneuroendocrinology. 1997;22 Suppl 1:S27-31 [9264144.001]
  • [Cites] Brain Res Brain Res Rev. 1999 Nov;30(3):264-88 [10567728.001]
  • [Cites] Nature. 1999 Nov 18;402(6759):304-9 [10580503.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):883-9 [10690906.001]
  • [Cites] Int J Dev Biol. 2000 Apr;44(3):309-16 [10853827.001]
  • [Cites] Clin Invest Med. 2000 Oct;23(5):300-10 [11055323.001]
  • [Cites] Eur J Endocrinol. 2000 Nov;143(5):687-95 [11078994.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1669-77 [11250949.001]
  • [Cites] Biochem J. 2001 Apr 15;355(Pt 2):509-15 [11284740.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:231-3; discussion 233-5 [11458512.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 15;767(2):285-99 [11885858.001]
  • [Cites] Mech Ageing Dev. 2002 Apr 30;123(8):1107-14 [12044960.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):748-59 [12360213.001]
  • [Cites] Calcif Tissue Int. 2002 Nov;71(5):429-36 [12196904.001]
  • [Cites] J Endocrinol. 2002 Dec;175(3):705-13 [12475381.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3499-509 [12493748.001]
  • [Cites] Lipids. 2002 Dec;37(12):1187-91 [12617473.001]
  • [Cites] Singapore Med J. 2002 Nov;43(11):576-8 [12680527.001]
  • [Cites] Mol Cell Endocrinol. 2003 May 30;203(1-2):13-23 [12782399.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):922-9 [14617568.001]
  • [Cites] Clin Exp Rheumatol. 2004 Jan-Feb;22(1):79-84 [15005008.001]
  • [Cites] Psychoneuroendocrinology. 1997;22 Suppl 1:S103-8 [9264155.001]
  • [Cites] J Burn Care Rehabil. 1997 Nov-Dec;18(6):483-9 [9404980.001]
  • [Cites] J Neuroimmunol. 1998 Apr 1;84(1):61-8 [9600709.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Jul;218(3):174-91 [9648935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13835-40 [9811887.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3591-5 [15529389.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):621-31 [15591536.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3600-5 [15755854.001]
  • [Cites] Vitam Horm. 2005;71:263-99 [16112271.001]
  • [Cites] Neth J Med. 2005 Sep;63(8):300-4 [16186639.001]
  • [Cites] J Endocrinol. 2005 Nov;187(2):169-96 [16293766.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3332-6 [15240611.001]
  • [Cites] Yale J Biol Med. 2003;76(2):45-54 [15369631.001]
  • [Cites] Drug Metab Rev. 2006;38(1-2):89-116 [16684650.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Aug;91(8):2986-93 [16735495.001]
  • [Cites] Calcif Tissue Int. 2006 Aug;79(2):118-25 [16927049.001]
  • [Cites] Cytokine. 2006 Oct;36(1-2):57-68 [17161616.001]
  • [Cites] Arthritis Res Ther. 2007;9(1):204 [17316462.001]
  • [Cites] J Mol Endocrinol. 2007 Apr;38(4):467-79 [17446236.001]
  • [Cites] Diabetes Care. 2007 Jun;30(6):1574-6 [17363747.001]
  • [Cites] PLoS One. 2007;2(6):e561 [17593962.001]
  • [Cites] Bone. 2007 Aug;41(2):297-302 [17561466.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S1 [17634140.001]
  • [Cites] Nat Cell Biol. 2007 Nov;9(11):1229-31 [17975548.001]
  • [Cites] J Am Soc Nephrol. 2008 Jan;19(1):92-101 [18032797.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):1936-45 [18045882.001]
  • [Cites] Mol Pharmacol. 2008 Mar;73(3):968-76 [18079279.001]
  • [Cites] Osteoporos Int. 2008 May;19(5):699-707 [18084691.001]
  • [Cites] Front Neuroendocrinol. 2008 May;29(2):169-81 [18093638.001]
  • [Cites] Arch Intern Med. 2008 Apr 28;168(8):820-5 [18443256.001]
  • (PMID = 21042414.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-androstene-3,7,17-triol; 0 / Androstenols
  • [Other-IDs] NLM/ PMC2958849
  •  go-up   go-down


57. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI: Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer; 2010 Oct;55(4):644-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation.
  • BACKGROUND: Cultured brain tumors can form neurospheres harboring tumorigenic cells with self renewal and differentiation capacities.
  • Renewable neurosphere formation has clinical predictive value in adult malignant gliomas, yet its prognostic role for pediatric brain tumors is unknown.
  • CONCLUSIONS: Neurosphere formation is more predictive of pediatric brain tumor progression than semi-quantitative Ki67 staining.
  • Pediatric brain tumor derived neurospheres may provide a predictive model for preclinical explorations.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):888-93 [17554787.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8205-12 [19088037.001]
  • [Cites] Stem Cells. 2009 Apr;27(4):980-7 [19353526.001]
  • [Cites] J Neurosurg Pediatr. 2009 Jun;3(6):461-6 [19485728.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):570-86 [19560746.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):312-7 [19434732.001]
  • [Cites] Curr Stem Cell Res Ther. 2009 Dec;4(4):298-305 [19500067.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5761-70 [19813274.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Clin Neuropathol. 2002 Nov-Dec;21(6):252-7 [12489673.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):914-20 [15223962.001]
  • (PMID = 20589659.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS052563; United States / NCI NIH HHS / CA / T32 CA009056; United States / NCI NIH HHS / CA / U54 CA119347; United States / NINDS NIH HHS / NS / R01NS052563
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS572199; NLM/ PMC4017922
  •  go-up   go-down


58. Fomchenko EI, Holland EC: Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg Clin N Am; 2007 Jan;18(1):39-58, viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment.
  • Many researchers view brain tumors as clonal entities derived from the cancer stem cell; however, recent documentation of the importance of the tumor microenvironment for glioma initiation and progression as well as the ability of neural stem or progenitor cells to migrate toward the sites of injury or tumor formation reveals additional complexities in brain tumorigenesis.
  • Paracrine effects of PDGF in animal models of gliomagenesis, continued adult neurogenesis capable of increasing in response to brain injury, and the growth factor-rich environment of brain tumors suggest that recruitment may play a role in gliomagenesis.
  • In this view, glioma formation involves recruitment of cells from the adjacent brain and possibly other sites.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Glioma / pathology. Glioma / physiopathology. Platelet-Derived Growth Factor / metabolism. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244553.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099489; United States / NCI NIH HHS / CA / R01 CA100688; United States / NCI NIH HHS / CA / U01 CA894314-1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor
  • [Number-of-references] 179
  •  go-up   go-down


59. Helton KJ, Phillips NS, Khan RB, Boop FA, Sanford RA, Zou P, Li CS, Langston JW, Ogg RJ: Diffusion tensor imaging of tract involvement in children with pontine tumors. AJNR Am J Neuroradiol; 2006 Apr;27(4):786-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Conventional MR imaging permits subcategorization of brain stem tumors by location and focality; however, assessment of white matter tract involvement by tumor is limited.
  • Diffusion tensor imaging (DTI) is a promising method for visualizing white matter tract tumor involvement supratentorially.
  • CONCLUSION: DTI provided superior visualization and quantification of tumor involvement in motor, sensory, and transverse pontine tracts, compared with information provided by conventional MR imaging.
  • Further prospective studies are warranted to assess the ability of DTI to delineate tumor focality and improve risk stratification in children with pontine tumors.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Infant, Newborn. Neoplasm Invasiveness. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16611765.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Tabatabai G, Herrmann C, von Kürthy G, Mittelbronn M, Grau S, Frank B, Möhle R, Weller M, Wick W: VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain; 2008 Oct;131(Pt 10):2579-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells.
  • Exposure of human cerebral endothelial cells (SV-HCEC), human microvascular endothelial cells (HMEC) and brain tumour endothelial cells derived from human glioblastomas (BTEC) to supernatants of glioma cells and primary glioma cells (SN-G) induced the expression of E-selectin (CD62E).
  • Tissue microarray sampling normal brain tissue and astrocytomas of WHO grades II-IV revealed a selective expression of CD62E on endothelial cells of tumour vessels.
  • [MeSH-major] Adult Stem Cells / metabolism. E-Selectin / metabolism. Endothelial Cells / metabolism. Glioma / metabolism. Hematopoietic Stem Cells / metabolism. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Autoantibodies / pharmacology. Cell Hypoxia. Cell Line, Tumor. Cell Migration Inhibition. Cell Movement. Coculture Techniques. Gene Expression. Humans. Mice. Mice, Mutant Strains. NF-kappa B / metabolism. Neoplasm Transplantation. Signal Transduction / physiology. Transforming Growth Factor beta / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689869.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / E-Selectin; 0 / NF-kappa B; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


61. Panagiotakos G, Tabar V: Brain tumor stem cells. Curr Neurol Neurosci Rep; 2007 May;7(3):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • The concept of brain tumor stem cells is gaining increased recognition in neuro-oncology.
  • Until recently, the paradigm of a tumor-initiating stem cell was confined to hematopoietic malignancies where the hierarchical lineages of stem progenitor cells are well established.
  • The demonstration of persistent stem cells and cycling progenitors in the adult brain, coupled with the expansion of the cancer stem cell concept to solid tumors, has led to the exploration of "stemness" within gliomas.
  • Emerging data are highly suggestive of the subsistence of transformed multipotential cells within a glioma, with a subfraction of cells exhibiting increased efficiency at tumor initiation.
  • However, data in support of true glioma stem cells are inconclusive to date, particularly with respect to functional characterization of these cells.
  • Ongoing work aims at the identification of unique pathways governing self-renewal of these putative stem cells and at their validation as ultimate therapeutic targets.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplastic Stem Cells / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2006 Jun 21;26(25):6781-90 [16793885.001]
  • [Cites] Exp Neurol. 1992 Jan;115(1):110-4 [1728556.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Cancer Res. 1969 Nov;29(11):1927-31 [4311561.001]
  • [Cites] Neuron Glia Biol. 2004 May;1(2):157-63 [17047730.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Neuron. 2006 Jul 20;51(2):187-99 [16846854.001]
  • [Cites] Acta Neuropathol. 1977 Apr 29;38(1):1-6 [193346.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Neuron. 1993 Feb;10(2):201-12 [8439409.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] J Comp Neurol. 2006 Jan 20;494(3):415-34 [16320258.001]
  • [Cites] Immunity. 1994 Nov;1(8):661-73 [7541305.001]
  • [Cites] Cell. 1999 Jun 11;97(6):703-16 [10380923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12846-51 [11070094.001]
  • [Cites] Nat Genet. 2000 May;25(1):55-7 [10802656.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:387-403 [11687494.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):612-3 [11826087.001]
  • [Cites] Acta Neuropathol. 1977 Sep 26;40(1):63-71 [199034.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):823-6 [16799564.001]
  • [Cites] J Neurosci. 1997 Jul 1;17(13):5046-61 [9185542.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Annu Rev Neurosci. 2001;24:385-428 [11283316.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2804-8 [1372992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2074-7 [8446631.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cancer. 2006 Dec 02;5:67 [17140455.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Exp Neurol. 2001 Nov;172(1):1-16 [11681836.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Nat Med. 2000 Apr;6(4):447-50 [10742153.001]
  • [Cites] J Neurosci. 2002 Feb 1;22(3):629-34 [11826091.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):52-9 [17178457.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14895-900 [8962152.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] J Neurobiol. 1998 Aug;36(2):221-33 [9712306.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11619-24 [10500226.001]
  • [Cites] Curr Biol. 2007 Jan 23;17 (2):165-72 [17196391.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1313-7 [9809557.001]
  • [Cites] Nat Med. 2003 Apr;9(4):439-47 [12627226.001]
  • (PMID = 17488587.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


62. Winestone JS, Lin J, Sanford RA, Boop FA: Subepyndemal hemangioblastomas of the cervicomedullary junction: lessons learned in the management of two cases. Childs Nerv Syst; 2007 Jul;23(7):761-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Careful monitoring for unique complications, treatment of the tumor as a vascular malformation, and screening for von Hippel Lindau must all be employed to safely care for this challenging group of patients.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Central Nervous System Vascular Malformations / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Cervical Vertebrae. Child, Preschool. Female. Humans. Male. Medulla Oblongata. Treatment Outcome. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1986 Feb;64(2):317-21 [3944644.001]
  • [Cites] Surg Neurol. 2001 Oct;56(4):218-26; discussion 226-7 [11738662.001]
  • [Cites] Surg Neurol. 1975 Aug;4(2):211-24 [1162593.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] Acta Neurochir (Wien). 2001 Sep;143(9):893-6 [11685621.001]
  • (PMID = 17396270.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Wu B, You C, Cai BW, He M, Shuai KG: [Therapeutic effect of far lateral approach on the lesions located ventral to cranial-cervical junction]. Zhonghua Wai Ke Za Zhi; 2005 May 1;43(9):612-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the administration of far-lateral approach in lesions located anterior or anterolateral to brain stem and upper cervical spinal cord.
  • RESULTS: Total tumor removal was achieved in 15 patients, subtotal removal in 5 patients, 3 vertibral artery aneurysms were clipped successfully, 3 patients were given occipitalcervical fusion.
  • The most frequent complications were lower cranial nerve deficit, CSF leakage, injury to vertibral artery, and ischemia of brain stem, cerebellum or spinal cord.
  • [MeSH-major] Aneurysm / surgery. Basilar Artery. Brain Neoplasms / surgery. Neurosurgical Procedures / methods. Vertebral Artery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Microsurgery. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Aneurysms.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938939.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Kim JY, Casaccia-Bonnefil P: Interplay of hormones and p53 in modulating gender dimorphism of subventricular zone cell number. J Neurosci Res; 2009 Nov 15;87(15):3297-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The number of Sox2(+) multipotential cells in the SVZ of young adult female mice was greater than in age-matched male siblings, but this difference was not evident prior to the surge of sex hormones (i.e., in prepubertal mice).

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4357-66 [10594662.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Eur J Neurosci. 2000 Jul;12(7):2414-24 [10947820.001]
  • [Cites] Exp Neurol. 2001 Jan;167(1):27-39 [11161590.001]
  • [Cites] Neuroscientist. 2001 Jun;7(3):258-70 [11499404.001]
  • [Cites] Mol Cell Neurosci. 2002 Jul;20(3):390-403 [12139917.001]
  • [Cites] Postgrad Med J. 2002 Aug;78(922):460-4 [12185217.001]
  • [Cites] J Neuroimmunol. 2002 Sep;130(1-2):211-23 [12225904.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13211-6 [12235363.001]
  • [Cites] Glia. 2003 Jan;41(1):73-80 [12465047.001]
  • [Cites] Mol Cell Neurosci. 2002 Nov;21(3):512-20 [12498791.001]
  • [Cites] Neurol Res. 2002 Dec;24(8):809-16 [12500705.001]
  • [Cites] Eur J Neurol. 2003 Jan;10(1):95-7 [12535003.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):688-94 [12700753.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):167-75 [14695330.001]
  • [Cites] Mol Cell Neurosci. 2003 Dec;24(4):1074-82 [14697670.001]
  • [Cites] J Neurochem. 2004 Mar;88(5):1179-85 [15009673.001]
  • [Cites] J Neuroimmunol. 2004 Apr;149(1-2):84-9 [15020068.001]
  • [Cites] J Neurochem. 2004 May;89(3):660-73 [15086523.001]
  • [Cites] Cell Death Differ. 2004 May;11(5):503-11 [14739940.001]
  • [Cites] J Neuroendocrinol. 2004 Aug;16(8):704-10 [15271063.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496-500 [3458212.001]
  • [Cites] J Steroid Biochem. 1988 Sep;31(3):287-93 [3419159.001]
  • [Cites] Can J Neurol Sci. 1992 Nov;19(4):466-71 [1423044.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2074-7 [8446631.001]
  • [Cites] Curr Opin Neurol Neurosurg. 1993 Apr;6(2):195-201 [8481563.001]
  • [Cites] Bioessays. 1995 Jun;17(6):545-8 [7575496.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jan;35(1-2):19-30 [8717336.001]
  • [Cites] Exp Neurol. 2006 Nov;202(1):250-4 [16797535.001]
  • [Cites] J Comp Neurol. 2007 Feb 20;500(6):1064-75 [17183542.001]
  • [Cites] J Reprod Immunol. 2007 Jun;74(1-2):90-102 [17275917.001]
  • [Cites] Dev Neurobiol. 2007 Jul;67(8):1107-17 [17565708.001]
  • [Cites] Cell Tissue Res. 2008 Jan;331(1):337-45 [17694326.001]
  • [Cites] J Biomed Sci. 2008 Mar;15(2):147-62 [17965948.001]
  • [Cites] Brain Res. 2008 Apr 24;1206:20-32 [18367155.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6237-43 [10843676.001]
  • [Cites] J Immunol. 1997 Jul 1;159(1):3-6 [9200430.001]
  • [Cites] J Pathol. 1997 Oct;183(2):177-81 [9390030.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6399-402 [9600977.001]
  • [Cites] N Engl J Med. 1998 Jul 30;339(5):285-91 [9682040.001]
  • [Cites] J Cell Biochem. 1998 Sep 15;70(4):442-54 [9712143.001]
  • [Cites] Science. 1999 Feb 26;283(5406):1277-8 [10084932.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):148-52 [10406979.001]
  • [Cites] Exp Neurol. 1999 Sep;159(1):225-36 [10486190.001]
  • [Cites] J Neurochem. 2005 Feb;92(3):569-84 [15659227.001]
  • [Cites] J Neurol Sci. 2005 Jun 15;233(1-2):49-54 [15878598.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Dec;64(12):1089-100 [16319719.001]
  • [Cites] J Neurosci. 2008 Jun 11;28(24):6118-27 [18550754.001]
  • (PMID = 19025772.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R0152738; United States / CSR NIH HHS / RG / RG-3553; United States / NINDS NIH HHS / NS / R01 NS052738-04; United States / NINDS NIH HHS / NS / R01 NS052738; United States / NINDS NIH HHS / NS / NS052738-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Gonadal Steroid Hormones; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Tumor Suppressor Protein p53; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS177627; NLM/ PMC2864025
  •  go-up   go-down


65. Zhai DZ, Huang Q, Zhu Q, Huo HM, Dong J, Qian ZY, Wang AD, Lan Q: [Expression of cyclin-dependent kinase CDC2 and its significance in malignant progression of gliomas]. Zhonghua Bing Li Xue Za Zhi; 2007 Mar;36(3):196-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Brain Neoplasms / metabolism. CDC2 Protein Kinase / metabolism. Glioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Bone Marrow / metabolism. Brain / metabolism. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Transplantation. Neoplastic Stem Cells / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535689.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


66. Garcia-Lavandeira M, Quereda V, Flores I, Saez C, Diaz-Rodriguez E, Japon MA, Ryan AK, Blasco MA, Dieguez C, Malumbres M, Alvarez CV: A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS One; 2009;4(3):e4815
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GRFa2/Prop1/stem (GPS) cell niche in the pituitary.
  • BACKGROUND: The adult endocrine pituitary is known to host several hormone-producing cells regulating major physiological processes during life.
  • Some candidates to progenitor/stem cells have been proposed.
  • However, not much is known about pituitary cell renewal throughout life and its homeostatic regulation during specific physiological changes, such as puberty or pregnancy, or in pathological conditions such as tumor development.
  • In addition, cells in the niche uniquely express the pituitary-specific transcription factor Prop1, as well as known progenitor/stem markers such as Sox2, Sox9 and Oct4.
  • Half of these GPS (GFRa2/Prop1/Stem) cells express S-100 whereas surrounding elongated cells in contact with GPS cells express Vimentin.
  • In vivo, GPSs cells display slow proliferation after birth, retain BrdU label and show long telomeres in its nuclei, indicating progenitor/stem cell properties in vivo.
  • SIGNIFICANCE: Our results suggest the presence in the adult pituitary of a specific niche of cells characterized by the expression of GFRa2, the pituitary-specific protein Prop1 and stem cell markers.
  • [MeSH-major] Glial Cell Line-Derived Neurotrophic Factor Receptors / metabolism. Pituitary Gland / cytology. Stem Cell Niche / metabolism. Stem Cells / cytology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Feb;18(2):147-9 [9462743.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1111-5 [9609310.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jul;83(7):2601-4 [9661653.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Neuron. 1999 Feb;22(2):243-52 [10069331.001]
  • [Cites] Neuron. 1999 Feb;22(2):253-63 [10069332.001]
  • [Cites] Nat Genet. 1999 May;22(1):44-52 [10319860.001]
  • [Cites] Acta Anat (Basel). 1951;11(2-3):361-82 [14829142.001]
  • [Cites] Hum Mol Genet. 2004 Nov 15;13(22):2727-35 [15459176.001]
  • [Cites] Dev Biol. 2005 Mar 1;279(1):114-24 [15708562.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):698-710 [15591534.001]
  • [Cites] Endocrinology. 2005 May;146(5):2376-87 [15677762.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):1-12 [15994739.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):166-76 [15916758.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67 [15982921.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):3985-98 [15932930.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1484-95 [11518797.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4529-35 [11549703.001]
  • [Cites] Development. 2002 Jan;129(2):329-37 [11807026.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Apr;87(4):1879-84 [11932334.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Nat Rev Neurosci. 2002 May;3(5):383-94 [11988777.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Mol Endocrinol. 2002 Nov;16(11):2645-56 [12403852.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):461-3 [12612584.001]
  • [Cites] Diabetes. 2003 Aug;52(8):2035-42 [12882920.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5261-9 [12917627.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1293-9 [12949502.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Am J Med Genet A. 2005 Oct 1;138A(2):95-8 [16145681.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):303-11 [16493421.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1654-63 [16384867.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1880-5 [16574858.001]
  • [Cites] Mol Endocrinol. 2006 Jun;20(6):1378-90 [16556738.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1075-9 [16810242.001]
  • [Cites] J Clin Invest. 2006 Sep;116(9):2442-55 [16932809.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2382-90 [16857898.001]
  • [Cites] Trends Pharmacol Sci. 2007 Feb;28(2):68-74 [17218019.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1743-51 [17062733.001]
  • [Cites] Endocrinology. 2007 Apr;148(4):1518-23 [17234709.001]
  • [Cites] EMBO J. 2007 Apr 18;26(8):2015-28 [17380130.001]
  • [Cites] Neuroendocrinology. 2007;85(2):110-30 [17337880.001]
  • [Cites] Development. 2007 Jun;134(11):2001-6 [17507401.001]
  • [Cites] Cell. 2007 Jun 15;129(6):1051-63 [17574020.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3496-506 [10880462.001]
  • [Cites] Cell. 2000 Aug 18;102(4):451-61 [10966107.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1141-53 [11371507.001]
  • [Cites] Development. 2004 Aug;131(15):3805-19 [15240551.001]
  • [Cites] Cell. 2004 Aug 20;118(4):493-504 [15315761.001]
  • [Cites] J Clin Invest. 2004 Sep;114(6):795-804 [15372103.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Oct;89(10):5256-65 [15472232.001]
  • [Cites] Endocrinol Jpn. 1977 Jun;24(3):301-5 [913340.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):555-63 [17563758.001]
  • [Cites] Physiol Rev. 2007 Jul;87(3):933-63 [17615393.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):2053-65 [17525237.001]
  • [Cites] Semin Cell Dev Biol. 2007 Aug;18(4):559-70 [17509912.001]
  • [Cites] Biol Reprod. 2007 Oct;77(4):723-33 [17625109.001]
  • [Cites] J Histochem Cytochem. 2007 Dec;55(12):1265-71 [17875653.001]
  • [Cites] Genome Biol. 2007;8(8):R163 [17683608.001]
  • [Cites] Cell. 2008 Jan 25;132(2):299-310 [18243104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2907-12 [18287078.001]
  • [Cites] Genes Dev. 2008 Mar 1;22(5):654-67 [18283121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6332-7 [18436641.001]
  • [Cites] Hepatology. 2008 Jun;47(6):1994-2002 [18454509.001]
  • [Cites] PLoS One. 2008;3(7):e2800 [18665239.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1489-93 [10688798.001]
  • [Cites] Cell Tissue Res. 2000 Mar;299(3):409-15 [10772255.001]
  • [Cites] Endocrinology. 2000 May;141(5):1893-6 [10803600.001]
  • [Cites] Brain Res. 1980 Jun 9;191(2):523-31 [6991054.001]
  • [Cites] Nature. 1984 Oct 4-10;311(5985):469-72 [6207435.001]
  • [Cites] Cell Tissue Res. 1988 Aug;253(2):419-24 [2457446.001]
  • [Cites] Anat Embryol (Berl). 1989;179(5):491-5 [2471422.001]
  • [Cites] Arch Histol Cytol. 1989 Jul;52(3):241-8 [2476166.001]
  • [Cites] Eur J Endocrinol. 1995 Jul;133(1):25-32 [7542980.001]
  • [Cites] Dev Biol. 1995 Dec;172(2):495-503 [8612966.001]
  • [Cites] Cell. 1996 May 31;85(5):721-32 [8646780.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(8):1002-7 [8890999.001]
  • [Cites] Nature. 1996 Nov 28;384(6607):327-33 [8934515.001]
  • (PMID = 19283075.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GFRA2 protein, human; 0 / Glial Cell Line-Derived Neurotrophic Factor Receptors; 0 / Homeodomain Proteins; 0 / Octamer Transcription Factor-3; 0 / Pituitary Hormones; 0 / Prophet of Pit-1 protein; 0 / Stage-Specific Embryonic Antigens; 0 / Transcription Factors; 0 / stage-specific embryonic antigen-4; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2654029
  •  go-up   go-down


67. Hafez RF: Stereotaxic gamma knife surgery in treatment of critically located pilocytic astrocytoma: preliminary result. World J Surg Oncol; 2007;5:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Low-grade gliomas are uncommon primary brain tumors, located more often in the posterior fossa, optic pathway, and brain stem and less commonly in the cerebral hemispheres.
  • CASE PRESENTATIONS: Two patients with diagnosed recurrent cystic pilocytic astrocytoma critically located within the brain (thalamic and brain stem) were treated with gamma knife surgery.
  • Progressive reduction on the magnetic resonance imaging (MRI) studies of the solid part of the tumor and almost disappearance of the cystic component was achieved within the follow-up period of 36 months in the first case with the (thalamic located lesion) and 22 months in the second case with the (brain stem located lesion).
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Thalamic Diseases / pathology. Thalamic Diseases / surgery. Young Adult

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):43-51 [12007940.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):677-80 [12507119.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1132-9; discussion [16331161.001]
  • [Cites] Neurochirurgie. 1998 Mar;44(1):50-4 [9757318.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:19-24 [15662774.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):374-9 [15667955.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2 [8692387.001]
  • (PMID = 17394660.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1852107
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


68. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB: Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol; 2010 Feb;96(3):359-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone.
  • Current therapies for glioblastoma (GBM) target bulk tumor through measures such as resection and radiotherapy.
  • However, recent evidence suggests that targeting a subset of tumor cells, so-called cancer stem cells, may be critical for inhibiting tumor growth and relapse.
  • The subventricular zone (SVZ), which lines the ventricles of the brain, is thought to be the origin for the majority of neural stem cells and potentially cancer stem cells.
  • Therefore, we assessed the relationship between tumor contact with the SVZ as determined by MRI, cancer stem cell gene expression and survival in 47 patients with GBM.
  • Using DNA microarrays, we found that genes associated with cancer stem cells were not over-expressed in tumors contacting the SVZ.
  • Thus we found no evidence of a stem-cell derived genetic signature specific for GBM in contact with the SVZ, but there was a relationship between stem cell gene expression and survival.
  • More research is required to clarify the relationship between the SVZ, cancer stem cells and survival.
  • [MeSH-major] Cerebral Ventricle Neoplasms. Cerebral Ventricles / pathology. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adult. Cell Differentiation. Cell Proliferation. Female. Gene Expression / physiology. Gene Expression Profiling / methods. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging / methods. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Proportional Hazards Models. Retrospective Studies

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):129-34 [19343483.001]
  • [Cites] Radiographics. 1996 Nov;16(6):1413-38; quiz 1462-3 [8946545.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):328-41 [15716863.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5515-25 [16061868.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] J Neurosci. 2006 Jan 25;26(4):1107-16 [16436596.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):981-7 [16964394.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Neuron. 2007 Feb 15;53(4):503-17 [17296553.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Nat Genet. 2007 Jun;39(6):759-69 [17468756.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul-Aug;1769(7-8):437-42 [17588684.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):424-9 [17622647.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6970-7 [18056172.001]
  • [Cites] Cancer Cell. 2008 Jan;13(1):69-80 [18167341.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):301-6 [18172323.001]
  • [Cites] J Neurosci Res. 2008 Jan;86(1):48-60 [17722061.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4541-50 [18559498.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):219-24 [18458819.001]
  • [Cites] Radiology. 2008 Oct;249(1):268-77 [18796682.001]
  • [Cites] Radiat Oncol. 2008;3:32 [18817556.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8205-12 [19088037.001]
  • [Cites] J Neurosurg. 2009 Jan;110(1):156-62 [18847342.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] J Clin Neurosci. 2009 Feb;16(2):195-201 [19097905.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:85 [19108713.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):318-27 [19330836.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • (PMID = 19655089.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808508
  •  go-up   go-down


69. Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tão H, Gomes F, Nieto AB, Resende Oliveira C, Lopes MC, Orfao A: Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology. Neuro Oncol; 2010 Sep;12(9):991-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.
  • Here, we analyzed the GEP (U133Plus2.0 chip) of 40 gliomas (35 astrocytic tumors, 3 oligodendrogliomas, and 2 mixed tumors) and their association with tumor cytogenetics and histopathology.
  • In turn, among glioblastoma multiforme (GBM), 3 subgroups of tumors were identified according to their GEP, which were closely associated with the cytogenetic profile of their ancestral tumor cell clones: (i) EGFR amplification, (ii) isolated trisomy 7, and (iii) more complex karyotypes.
  • In summary, our results show a clear association between the GEP of gliomas and tumor histopathology; additionally, among grade IV astrocytoma, GEP are significantly associated with the cytogenetic profile of the ancestral tumor cell clone.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Gene Expression Profiling. Glioblastoma / genetics. Glioblastoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Cytogenetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2003 May-Jun;2(3):242-7 [12878856.001]
  • [Cites] PLoS Med. 2009 Jan 13;6(1):e10 [19143470.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7820-6 [15585613.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1087-98 [16731740.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17492-500 [16627485.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 15;351(2):336-9 [17067552.001]
  • [Cites] Int J Oncol. 2007 Jan;30(1):55-64 [17143512.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8 [17146292.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] Int J Oncol. 2001 Oct;19(4):673-80 [11562740.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Histol Histopathol. 2007 Mar;22(3):327-35 [17163407.001]
  • [Cites] Pathol Oncol Res. 2007;13(1):39-46 [17387387.001]
  • [Cites] Cell Mol Life Sci. 2007 Apr;64(7-8):796-802 [17364146.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1133-9 [17341657.001]
  • [Cites] Stem Cells. 2007 Jun;25(6):1498-506 [17322106.001]
  • [Cites] J Neurooncol. 2007 Oct;85(1):11-24 [17634744.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1225-36 [17962616.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7341-56 [18094416.001]
  • [Cites] J Neurooncol. 2008 Feb;86(3):297-309 [17928955.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):225-35 [18156210.001]
  • [Cites] Clin Transl Oncol. 2008 Feb;10(2):73-7 [18258505.001]
  • [Cites] Apoptosis. 2008 Mar;13(3):437-47 [18188704.001]
  • [Cites] Brain Res. 2008 Mar 27;1201:161-6 [18331723.001]
  • [Cites] Br J Cancer. 2008 Jun 3;98(11):1830-8 [18506188.001]
  • [Cites] Cell. 2009 Feb 6;136(3):473-84 [19203582.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2712-6 [19196966.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] J Biol Chem. 2008 Jun 13;283(24):16673-81 [18424444.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73 [18559551.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] Mol Diagn Ther. 2008;12(4):199-208 [18652516.001]
  • [Cites] Ann Diagn Pathol. 2008 Oct;12(5):313-21 [18774492.001]
  • [Cites] J Immunol Methods. 2008 Nov 30;339(1):74-81 [18775433.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2955-60 [18770864.001]
  • [Cites] Neurogenetics. 2010 May;11(2):227-39 [19760258.001]
  • (PMID = 20484145.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2940695
  •  go-up   go-down


70. Ueoka DI, Nogueira J, Campos JC, Maranhão Filho P, Ferman S, Lima MA: Brainstem gliomas--retrospective analysis of 86 patients. J Neurol Sci; 2009 Jun 15;281(1-2):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brainstem gliomas--retrospective analysis of 86 patients.
  • Brainstem gliomas constitute 10% of brain tumors in children and less than 2% in adults.
  • Since therapeutic options are limited and brainstem gliomas are associated with a high morbidity and mortality, we sought to analyze the prognostic factors associated with a better outcome.
  • We reviewed the records of 86 patients with brainstem gliomas treated between 1996 and 2006.
  • Of 86 patients with brainstem gliomas, 55.8% were females.
  • A short duration of symptoms, which may imply a more aggressive tumor, was associated with a worst prognosis in patients with brainstem gliomas.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Brain Stem / pathology. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345380.001).
  • [ISSN] 1878-5883
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Ahmed RP, Haider KH, Shujia J, Afzal MR, Ashraf M: Sonic Hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/netrin-1/PKC pathway. PLoS One; 2010 Jan 05;5(1):e8576
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We hypothesized that genetic modification of mesenchymal stem cells (MSCs) with Sonic Hedgehog (Shh) transgene, a morphogen during embryonic development and embryonic and adult stem cell growth, improved their survival and angiogenic potential in the ischemic heart via iNOS/netrin/PKC pathway.
  • CONCLUSIONS/SIGNIFICANCE: Reprogramming of stem cells with Shh maximizes their survival and angiogenic potential in the heart via iNOS/netrin-1/PKC signaling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2002 Jun;54(3):659-68 [12031712.001]
  • [Cites] Biochem J. 2001 Aug 1;357(Pt 3):593-615 [11463332.001]
  • [Cites] Circulation. 2003 Jul 29;108(4):479-85 [12860919.001]
  • [Cites] Hypertension. 1992 Nov;20(5):585-95 [1428108.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):126-38 [7589793.001]
  • [Cites] Trends Genet. 1996 Dec;12(12):496-7 [9257526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16210-5 [15520390.001]
  • [Cites] Circ Res. 2005 Jan 7;96(1):127-37 [15569828.001]
  • [Cites] Nat Med. 2005 Apr;11(4):367-8 [15812508.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):22-47 [15960985.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1197-204 [16244652.001]
  • [Cites] World J Gastroenterol. 2005 Oct 14;11(38):5931-7 [16273602.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):839-45 [16424016.001]
  • [Cites] Science. 2006 Aug 4;313(5787):640-4 [16809490.001]
  • [Cites] J Vasc Res. 2006;43(5):462-72 [16921253.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1222-32 [16990385.001]
  • [Cites] Circ Res. 2006 Sep 29;99(7):776-84 [16960098.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] J Exp Biol. 2007 Nov;210(Pt 22):4053-64 [17981873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17783-8 [17965233.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3069-80 [17901397.001]
  • [Cites] Circ Res. 2008 Nov 21;103(11):1300-8 [18948617.001]
  • [Cites] Carcinogenesis. 2009 Apr;30(4):580-8 [19168578.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2424-35 [18662193.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):312-9 [10559945.001]
  • [Cites] Nat Med. 2001 Jun;7(6):706-11 [11385508.001]
  • [Cites] Lancet. 2003 Jan 4;361(9351):45-6 [12517467.001]
  • (PMID = 20052412.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL089535; United States / NHLBI NIH HHS / HL / HL087246; United States / NHLBI NIH HHS / HL / R01 HL087288; United States / NHLBI NIH HHS / HL / R01 HL087246; United States / NHLBI NIH HHS / HL / #R37-HL074272; United States / NHLBI NIH HHS / HL / HL-080686; United States / NHLBI NIH HHS / HL / R01 HL080686; United States / NHLBI NIH HHS / HL / R37 HL074272; United States / NHLBI NIH HHS / HL / HL089535; United States / NHLBI NIH HHS / HL / HL087288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Nerve Growth Factors; 0 / Tumor Suppressor Proteins; 158651-98-0 / netrin-1; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ PMC2797399
  •  go-up   go-down


72. Moviglia GA, Carrizo AG, Varela G, Gaeta CA, Paes de Lima A, Farina P, Molina H: Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther; 2008 Jan-Mar;1(1):3-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme.
  • BACKGROUND: Glioblastoma multiforme (GBM), the most aggressive glioma, presents with a rapid evolution and relapse within the first year, which is attributed to the persistence of tumor stem cells (TSC) and the escape of immune surveillance.
  • Tumor B-cell hybridoma (TBH) vaccines have been shown to function as antigen-presenting cells.
  • RESULTS: Treatment with MLC had strong and rapid therapeutic effects, but was limited in duration and induced various degrees of brain inflammation.
  • Treatment with MLC+TBH acted synergistically, provoking a rapid, strong and lasting therapeutic response but also generating different degrees of brain inflammation.
  • A lasting therapeutic effect without generating high degrees of brain inflammation occurred in patients treated with TBH vaccine alone.
  • CONCLUSION: TSC vaccine consisting of TBH alone seems to have potent adjuvant reactions overcoming both persistence of tumor stem cells and immune escape of GBM without provoking an encephalitic reaction.
  • [MeSH-major] B-Lymphocytes / transplantation. Brain Neoplasms / therapy. Cancer Vaccines / therapeutic use. Glioblastoma / therapy. Hybridomas / transplantation. Neoplastic Stem Cells / transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Leukocytes, Mononuclear / immunology. Leukocytes, Mononuclear / transplantation. Lymphocyte Culture Test, Mixed. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063522.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


73. Galli R, Gritti A, Vescovi AL: Adult neural stem cells. Methods Mol Biol; 2008;438:67-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neural stem cells.
  • Neural stem cells (NSCs) have been identified in the mature central nervous system (CNS), and they reside in specific areas.
  • The proper application of this method to the cells allows the establishment of long-term expanding stable NSC lines, starting from different neural tissues as the adult rodent CNS and human brain tumor specimens.
  • [MeSH-major] Cell Culture Techniques / methods. Neurons / cytology. Stem Cells / cytology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Separation. Cells, Cultured. Central Nervous System / cytology. Central Nervous System / pathology. Dissection. Humans. Neoplastic Stem Cells / cytology. Rodentia

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18369750.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ris MD, Beebe DW: Neurodevelopmental outcomes of children with low-grade gliomas. Dev Disabil Res Rev; 2008;14(3):196-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a group, children with low-grade gliomas (LGGs) enjoy a high rate of long-term survival and do not require the intensity of neurotoxic treatments used with higher risk pediatric brain tumors.
  • Because they are generally considered to have favorable neurobehavioral outcomes, they have not been studied as thoroughly as higher-grade brain tumors by late-effects researchers.
  • In this article, we review the literature on the neurobehavioral effects associated with low-grade gliomas and conclude that, (1) this is a large, understudied group of survivors of pediatric brain tumors;.
  • (3) such risk is not uniform but varies with tumor location and treatments; and (4) a life span development perspective is essential to a complete understanding of the risks faced by these children.
  • [MeSH-major] Brain Damage, Chronic / etiology. Brain Neoplasms / therapy. Child Behavior Disorders / etiology. Cognition Disorders / etiology. Developmental Disabilities / etiology. Glioma / therapy. Survivors / psychology
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / therapy. Cerebellar Neoplasms / therapy. Child. Combined Modality Therapy. Follow-Up Studies. Humans. Risk Factors. Supratentorial Neoplasms / therapy. Young Adult


75. Kim CH, Chung KW, Kong DS, Nam DH, Park K, Kim JH, Hong SH, Cho YS, Chung WH, Lee JI: Prognostic factors of hearing preservation after gamma knife radiosurgery for vestibular schwannoma. J Clin Neurosci; 2010 Feb;17(2):214-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor growth was controlled in 26 of the 27 patients (96.3%), and rates of hearing preservation were 85.1% and 68.1% at 2 and 3 years, respectively.
  • A normal auditory brainstem response (ABR) (p = 0.008) and Gardner-Robertson class I hearing (p = 0.012) before GKRS were found to be significant prognostic factors of a favorable outcome.
  • [MeSH-minor] Adult. Aged. Cochlear Nerve / pathology. Cochlear Nerve / radiation effects. Cochlear Nerve / surgery. Electroencephalography. Evoked Potentials, Auditory, Brain Stem / physiology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Preoperative Care. Prognosis. Prospective Studies. Radiation Dosage. Vestibular Nerve / pathology. Vestibular Nerve / radiography. Vestibular Nerve / surgery. Young Adult

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20056421.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


76. Peng H, Huang Y, Duan Z, Erdmann N, Xu D, Herek S, Zheng J: Cellular IAP1 regulates TRAIL-induced apoptosis in human fetal cortical neural progenitor cells. J Neurosci Res; 2005 Nov 1;82(3):295-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neural stem/progenitor cells (NPCs) are present in the developing and adult central nervous system.
  • NPC apoptosis is an important aspect of normal brain development.
  • We show that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 is highly expressed on human NPCs derived from fetal cortex, yet TRAIL induces only minimal levels of apoptosis in NPCs.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / metabolism. Brain / embryology. Inhibitor of Apoptosis Proteins / metabolism. Membrane Glycoproteins / metabolism. Neurons / metabolism. Stem Cells / metabolism. Tumor Necrosis Factor-alpha / metabolism
  • [MeSH-minor] Caspase 3. Caspase 8. Caspases / genetics. Cells, Cultured. Cerebral Cortex / embryology. Cerebral Cortex / growth & development. Cerebral Cortex / metabolism. Dactinomycin / pharmacology. Enzyme Activation / drug effects. Enzyme Activation / genetics. Fetus. Humans. Nerve Degeneration / metabolism. Nerve Degeneration / physiopathology. Protein Synthesis Inhibitors / pharmacology. RNA Interference / physiology. RNA, Messenger / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand. Receptors, Tumor Necrosis Factor / metabolism. TNF-Related Apoptosis-Inducing Ligand. Ubiquitin-Protein Ligases. Up-Regulation / drug effects. Up-Regulation / genetics

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16180223.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS043985; United States / NCRR NIH HHS / RR / P20 RR15635; United States / NINDS NIH HHS / NS / R01 NS 41858
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BIRC2 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Membrane Glycoproteins; 0 / Protein Synthesis Inhibitors; 0 / RNA, Messenger; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10B protein, human; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 1CC1JFE158 / Dactinomycin; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


77. Kang SK, Cha SH, Jeon HG: Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev; 2006 Apr;15(2):165-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies first proved that curcumin induces histone hypoacetylation in brain cancer cells and finally induces apoptotic cell death through a (PARP)- and caspase 3-mediated manner.
  • In addition, curcumin induces recontrolling of neural stem cell fates.
  • It induces effective neurogenesis, synaptogenesis, and migration of neural progenitor cells in vitro in brain-derived adult neural stem cells.
  • We suggest that histone hypoacetylation plays an important role in determine stem cell fate through controlling the simultaneous expression of many genes.
  • Thus, the present finding that curcumin, a nontoxic dietary compound, is a histone acetyltransferase inhibitor would supply a new window to understand further the molecular mechanism of histone acetylase inhibitors (HAI) in cancer and neural stem cells and provide a new target molecule for treating central nervous system disorders.
  • [MeSH-major] Apoptosis / drug effects. Caspases / metabolism. Curcumin / pharmacology. Histones / metabolism. Neurons / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Acetylation / drug effects. Animals. Astrocytes / cytology. Astrocytes / drug effects. Astrocytes / metabolism. Brain / cytology. Brain / drug effects. Brain / metabolism. Caspase 3. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Cell Survival / drug effects. Cells, Cultured. Collagen Type XI / metabolism. Dentate Gyrus / cytology. Dentate Gyrus / drug effects. Dentate Gyrus / metabolism. Glioma / metabolism. Glioma / pathology. Histone Acetyltransferases / antagonists & inhibitors. Humans. Mice. Mice, Inbred ICR. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. CURCUMIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16646663.001).
  • [ISSN] 1547-3287
  • [Journal-full-title] Stem cells and development
  • [ISO-abbreviation] Stem Cells Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / COL11A2 protein, human; 0 / Collagen Type XI; 0 / Histones; 0 / bcl-2-Associated X Protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; IT942ZTH98 / Curcumin
  •  go-up   go-down


78. Lavado A, Lagutin OV, Chow LM, Baker SJ, Oliver G: Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol; 2010 Aug 17;8(8)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis.
  • The dentate gyrus has an important role in learning and memory, and adult neurogenesis in the subgranular zone of the dentate gyrus may play a role in the acquisition of new memories.
  • The homeobox gene Prox1 is expressed in the dentate gyrus during embryonic development and adult neurogenesis.
  • Here we show that Prox1 is necessary for the maturation of granule cells in the dentate gyrus during development and for the maintenance of intermediate progenitors during adult neurogenesis.
  • We also demonstrate that Prox1-expressing intermediate progenitors are required for adult neural stem cell self-maintenance in the subgranular zone; thus, we have identified a previously unknown non-cell autonomous regulatory feedback mechanism that controls adult neurogenesis in this region of the mammalian brain.
  • Finally, we show that the ectopic expression of Prox1 induces premature differentiation of neural stem cells.
  • [MeSH-major] Cell Differentiation. Dentate Gyrus / cytology. Homeodomain Proteins / pharmacology. Neural Stem Cells / cytology. Neurogenesis / drug effects. Tumor Suppressor Proteins / pharmacology
  • [MeSH-minor] Adult Stem Cells / cytology. Animals. Brain / embryology. Female. Mice. Neurons / cytology. Neurons / metabolism


79. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M: Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A; 2006 Aug 1;103(31):11784-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vaccination apparently exerted its effect by causing a phenotype switch in brain microglia to dendritic-like (CD11c) cells producing insulin-like growth factor 1.
  • In vitro findings showed that microglia activated by aggregated beta-amyloid, and characterized as CD11b(+)/CD11c(-)/MHC class II(-)/TNF-alpha(+) cells, impeded neurogenesis from adult neural stem/progenitor cells, whereas CD11b(+)/CD11c(+)/MHC class II(+)/TNF-alpha(-) microglia, a phenotype induced by IL-4, counteracted the adverse beta-amyloid-induced effect.
  • These results suggest that dendritic-like microglia, by facilitating the necessary adjustment, might contribute significantly to the brain's resistance to AD and argue against the use of antiinflammatory drugs.
  • [MeSH-minor] Amyloid beta-Protein Precursor / genetics. Amyloid beta-Protein Precursor / metabolism. Animals. Antigens, CD11b / metabolism. Antigens, CD11c / metabolism. Genes, MHC Class II. Glatiramer Acetate. Hippocampus / cytology. Hippocampus / metabolism. Interleukin-4 / metabolism. Maze Learning. Membrane Proteins / genetics. Membrane Proteins / metabolism. Mice. Mice, Transgenic. Phenotype. Plaque, Amyloid / metabolism. Plaque, Amyloid / pathology. Presenilin-1. T-Lymphocytes / physiology. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Neurosci. 2000 Dec;1(3):191-8 [11257907.001]
  • [Cites] J Clin Invest. 2000 Apr;105(7):967-76 [10749576.001]
  • [Cites] Neuroscience. 2001;107(4):603-13 [11720784.001]
  • [Cites] Science. 2002 Jul 19;297(5580):353-6 [12130773.001]
  • [Cites] Brain. 2002 Nov;125(Pt 11):2381-91 [12390966.001]
  • [Cites] Hippocampus. 2002;12(5):578-84 [12440573.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15620-5 [12429857.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4790-5 [12668759.001]
  • [Cites] J Immunol. 2003 Nov 15;171(10):5482-8 [14607954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13632-7 [14581618.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1760-5 [14615545.001]
  • [Cites] Hum Mol Genet. 2004 Jan 15;13(2):159-70 [14645205.001]
  • [Cites] J Neuroimmunol. 2004 Jan;146(1-2):84-93 [14698850.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(2):234-46 [14725617.001]
  • [Cites] J Neurosci. 2000 Apr 15;20(8):2896-903 [10751442.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7446-51 [10861010.001]
  • [Cites] Nat Med. 2000 Aug;6(8):916-9 [10932230.001]
  • [Cites] J Clin Invest. 2005 Sep;115(9):2423-33 [16100572.001]
  • [Cites] J Mol Med (Berl). 2005 Nov;83(11):904-16 [16096740.001]
  • [Cites] J Alzheimers Dis. 2005 Dec;8(3):247-68 [16340083.001]
  • [Cites] Mol Cell Neurosci. 2006 Jan;31(1):149-60 [16297637.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):268-75 [16415867.001]
  • [Cites] Neuron. 2006 Feb 16;49(4):489-502 [16476660.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):905-15 [16557302.001]
  • [Cites] FASEB J. 2004 Jun;18(9):998-1000 [15084516.001]
  • [Cites] J Neurosci Res. 2004 Jul 1;77(1):1-8 [15197750.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9435-40 [15197276.001]
  • [Cites] J Neuroimmunol. 1990 Nov;30(1):81-93 [1977769.001]
  • [Cites] Neuron. 1991 Apr;6(4):487-98 [1673054.001]
  • [Cites] J Neuroimmunol. 1996 Feb;64(2):209-17 [8632064.001]
  • [Cites] Neuron. 1997 Oct;19(4):939-45 [9354339.001]
  • [Cites] Neuroreport. 1998 Mar 30;9(5):871-4 [9579682.001]
  • [Cites] Nat Med. 1999 Jan;5(1):49-55 [9883839.001]
  • [Cites] J Exp Med. 1999 Mar 1;189(5):865-70 [10049950.001]
  • [Cites] Eur J Immunol. 2004 Dec;34(12):3434-45 [15549735.001]
  • [Cites] J Neurochem. 2005 Mar;92(5):997-1009 [15715651.001]
  • [Cites] Cell. 2005 Mar 11;120(5):701-13 [15766532.001]
  • [Cites] Nat Med. 2005 May;11(5):545-50 [15834426.001]
  • [Cites] Mol Cell Neurosci. 2005 Jul;29(3):381-93 [15890528.001]
  • [Cites] FASEB J. 2001 Apr;15(6):1065-7 [11292669.001]
  • (PMID = 16864778.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Antigens, CD11b; 0 / Antigens, CD11c; 0 / Immunosuppressive Agents; 0 / Membrane Proteins; 0 / Peptides; 0 / Presenilin-1; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 5M691HL4BO / Glatiramer Acetate; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC1544247
  •  go-up   go-down


80. Tanaka S, Kobayashi I, Utsuki S, Iwamoto K, Takanashi J: Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report. Neurol Med Chir (Tokyo); 2005 Jan;45(1):49-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biopsy of brain stem glioma using motor-evoked potential mapping by direct peduncular stimulation and individual adjuvant therapy. Case report.
  • A 23-year-old man presented with a brain stem glioma manifesting as a 6-month history of right hemiparesis and diplopia.
  • Serial magnetic resonance imaging showed an intrinsic diffuse brain stem glioma that gradually localized to the left cerebral peduncle after initial adjuvant therapy.
  • Partial resection of the tumor was safely performed, with slight temporary neurological worsening.
  • Individual adjuvant therapy based on the results of real-time reverse transcription-polymerase chain reaction of O6-methylguanine-deoxyribonucleic acid methyltransferase achieved an almost complete tumor response.
  • Surgery under pyramidal tract mapping and intensive postoperative adjuvant therapy resulted in a good outcome despite the presence of a generally intractable intrinsic brain stem glioma.
  • [MeSH-major] Astrocytoma / surgery. Brain Mapping. Brain Stem Neoplasms / surgery. Evoked Potentials, Motor. Mesencephalon / physiopathology. Neurosurgical Procedures / methods
  • [MeSH-minor] Adult. Biopsy / methods. Humans. Male

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699622.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Komatani H, Sugita Y, Arakawa F, Ohshima K, Shigemori M: Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int J Oncol; 2009 Mar;34(3):665-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CXCL12, an alpha-chemokine that binds to G-protein-coupled CXCR4, plays an important and unique role in the regulation of stem/progenitor cell trafficking.
  • To elucidate the correlation between the CXCR4/CXCL12 axis and glioblastomas (GBs), the present study assessed CXCR4/CXCL12 expression in 44 astrocytic tumor tissues using immunohistochemical analyses.
  • Several cell lines of brain tumors were also analyzed by RT-PCR analyses.
  • Regarding CXCR4, widespread positive immunoreactivity was noted in the tumor cells in almost all cases of GBs.
  • Taken together, these results suggest that secretion of CXCR4/CXCL12 by hypoxic pseudopalisading and proliferating microvascular cells contributes to an outward migration of tumor cells away from hypoxia, creating a peripherally moving wave and subsequent microvascular proliferation.
  • [MeSH-major] Brain Neoplasms / blood supply. Chemokine CXCL12 / biosynthesis. Glioblastoma / blood supply
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / blood supply. Astrocytoma / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Movement / physiology. Child. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212671.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chemokine CXCL12
  •  go-up   go-down


82. Francesco F, Maurizio I, Stefano C, Marina S, Ugo S, Massimo S: Trigeminal nerve root entry zone pilocytic astrocytoma in an adult: a rare case of an extraparenchymal tumor. J Neurooncol; 2010 Apr;97(2):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trigeminal nerve root entry zone pilocytic astrocytoma in an adult: a rare case of an extraparenchymal tumor.
  • Extra-axial cerebellopontine angle (CPA) tumors account for approximately 10% of all brain neoplasms in adults.
  • Gliomas in the CPA are rare and quite often are the exophytic extension of primary brain stem or cerebellar tumors.
  • We describe a pilocytic astrocytoma of the CPA that was found to arise from the proximal portion of trigeminal nerve without any anatomic continuity with the brain stem and the cerebellum.
  • The proposed origin of this extremely rare tumor is the root entry zone of the involved nerve.
  • The tumor was completely resected via a suboccipital retrosigmoid approach.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1980 Aug;106(8):456-9 [7396789.001]
  • [Cites] J Laryngol Otol. 1980 Dec;94(12):1353-62 [7441048.001]
  • [Cites] Surg Neurol. 2008 Jul;70(1):87-91 [18313733.001]
  • [Cites] J Neuropathol Exp Neurol. 1948 Oct;7(4):349-67 [18889208.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):859-63 [8487066.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):205-12 [11212899.001]
  • [Cites] Eur Radiol. 2004 Jul;14(7):1169-73 [14740164.001]
  • [Cites] Neuroradiology. 1993;35(4):274-8 [8492893.001]
  • [Cites] Bull Johns Hopkins Hosp. 1948 Sep;83(3):187-212 [18877371.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4):E939-40; discussion E940 [17038929.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):125-8 [8587672.001]
  • [Cites] Childs Nerv Syst. 2009 Feb;25(2):247-51 [18690462.001]
  • [Cites] Am J Otolaryngol. 1980 Feb;1(2):141-6 [7446836.001]
  • (PMID = 19820900.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Jasmin JF, Yang M, Iacovitti L, Lisanti MP: Genetic ablation of caveolin-1 increases neural stem cell proliferation in the subventricular zone (SVZ) of the adult mouse brain. Cell Cycle; 2009 Dec;8(23):3978-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic ablation of caveolin-1 increases neural stem cell proliferation in the subventricular zone (SVZ) of the adult mouse brain.
  • Adult neural stem cells are self-renewing multipotent cells that have the potential to replace dysfunctional and/or dying neuronal cells at the site of brain injury or degeneration.
  • Caveolins are well-known tumor-suppressor genes that were recently found to be involved in the regulation of stem cell proliferation.
  • For instance, ablation of the caveolin-1 (Cav-1) gene in mice markedly increases the proliferation of intestinal and mammary stem cells.
  • However, the roles of caveolins in the proliferation of adult neural stem cells still remain unknown.
  • In this study, dual-label immunofluorescence analysis of the proliferation marker, Ki67, and the stem cell markers, nestin and Sox2, was performed on brains of 8 week-old wild-type (WT) and Cav-1 knockout (KO) mice.
  • Remarkably similar results were also obtained with Cav-2 and Cav-3 KO mouse brains as well, with increased proliferation of adult neural stem cells.
  • Thus, the SVZ of caveolin KO mouse brains displays an increased proliferation of adult neural stem cells.
  • Caveolin proteins might represent new crucial regulators of adult neural stem cell proliferation.
  • [MeSH-major] Brain / metabolism. Caveolin 1 / metabolism. Cerebral Ventricles / cytology. Neurons / cytology. Stem Cells / cytology